10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2024

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from              to              

Commission file numbers: 001-34465

SELECT MEDICAL HOLDINGS CORPORATION

(Exact name of Registrant as specified in its Charter)

Delaware	20-1764048
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification Number)

4714 Gettysburg Road, P.O. Box 2034

Mechanicsburg, PA 17055

(Address of Principal Executive Offices and Zip code)

(717) 972-1100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	SEM	New York Stock Exchange
		(NYSE)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as such Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ☒  No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).   Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging Growth Company	☐

 If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒

As of April 30, 2024, Select Medical Holdings Corporation had outstanding 130,031,562 shares of common stock.

Unless the context indicates otherwise, any reference in this report to “Holdings” refers to Select Medical Holdings Corporation and any reference to “Select” refers to Select Medical Corporation, the wholly owned operating subsidiary of Holdings, and any of Select’s subsidiaries. Any reference to “Concentra” refers to Concentra Group Holdings Parent, LLC (“Concentra Group Holdings Parent”) and its subsidiaries, including Concentra Inc. References to the “Company,” “we,” “us,” and “our” refer collectively to Holdings, Select, and Concentra.

1

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION	3
ITEM 1.	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
	Condensed consolidated balance sheets	3
	Condensed consolidated statements of operations	4
	Condensed consolidated statements of comprehensive income	5
	Condensed consolidated statements of changes in equity and income	6
	Condensed consolidated statements of cash flows	7
	Notes to condensed consolidated financial statements	8
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	18
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	33
ITEM 4.	CONTROLS AND PROCEDURES	33
PART II	OTHER INFORMATION	34
ITEM 1.	LEGAL PROCEEDINGS	34
ITEM 1A.	RISK FACTORS	34
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	34
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	34
ITEM 4.	MINE SAFETY DISCLOSURES	34
ITEM 5.	OTHER INFORMATION	34
ITEM 6.	EXHIBITS	35
SIGNATURES

2

PART I: FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Select Medical Holdings Corporation

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

	December 31, 2023		March 31, 2024
ASSETS
Current Assets:
Cash and cash equivalents	$	84,006	$	92,620
Accounts receivable	940,335		1,134,788
Prepaid income taxes	22,726		9,034
Current portion of interest rate cap contract	58,962		42,660
Other current assets	151,617		161,238
Total Current Assets	1,257,646		1,440,340
Operating lease right-of-use assets	1,188,616		1,176,713
Property and equipment, net	1,023,561		1,024,626
Goodwill	3,513,170		3,517,071
Identifiable intangible assets, net	329,916		324,125
Other assets	376,722		375,388
Total Assets	$	7,689,631	$	7,858,263
LIABILITIES AND EQUITY
Current Liabilities:
Overdrafts	$	30,274	$	28,534
Current operating lease liabilities	245,400		245,617
Current portion of long-term debt and notes payable	70,329		60,184
Accounts payable	174,312		163,551
Accrued and other liabilities	728,150		686,491
Total Current Liabilities	1,248,465		1,184,377
Non-current operating lease liabilities	1,025,867		1,015,160
Long-term debt, net of current portion	3,587,675		3,758,631
Non-current deferred tax liability	143,306		133,987
Other non-current liabilities	110,303		100,175
Total Liabilities	6,115,616		6,192,330
Commitments and contingencies (Note 14)
Redeemable non-controlling interests	26,297		28,290
Stockholders’ Equity:
Common stock, $0.001 par value, 700,000,000 shares authorized, 128,369,492 and 128,357,832 shares issued and outstanding at 2023 and 2024, respectively	128		128
Capital in excess of par	493,413		505,403
Retained earnings	751,856		830,821
Accumulated other comprehensive income	42,907		30,930
Total Stockholders’ Equity	1,288,304		1,367,282
Non-controlling interests	259,414		270,361
Total Equity	1,547,718		1,637,643
Total Liabilities and Equity	$	7,689,631	$	7,858,263

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

Select Medical Holdings Corporation

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except per share amounts)

	For the Three Months Ended March 31,
	2023		2024
Revenue	$	1,664,980	$	1,788,809
Costs and expenses:
Cost of services, exclusive of depreciation and amortization	1,418,819		1,494,610
General and administrative	42,279		48,447
Depreciation and amortization	52,425		54,069
Total costs and expenses	1,513,523		1,597,126
Other operating income	—		2,284
Income from operations	151,457		193,967
Other income and expense:
Equity in earnings of unconsolidated subsidiaries	8,556		10,421
Interest expense	(48,571)		(50,763)
Income before income taxes	111,442		153,625
Income tax expense	26,185		36,458
Net income	85,257		117,167
Less: Net income attributable to non-controlling interests	14,452		20,270
Net income attributable to Select Medical Holdings Corporation	$	70,805	$	96,897
Earnings per common share (Note 13):
Basic and diluted	$	0.56	$	0.75

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Select Medical Holdings Corporation

Condensed Consolidated Statements of Comprehensive Income

(unaudited)

(in thousands)

	For the Three Months Ended March 31,
	2023		2024
Net income	$	85,257	$	117,167
Other comprehensive loss, net of tax:
Gain (loss) on interest rate cap contract	(2,696)		4,370
Reclassification adjustment for gains included in net income	(13,252)		(16,347)
Net change, net of tax benefit of $5,175, and $3,782	(15,948)		(11,977)
Comprehensive income	69,309		105,190
Less: Comprehensive income attributable to non-controlling interests	14,452		20,270
Comprehensive income attributable to Select Medical Holdings Corporation	$	54,857	$	84,920

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Select Medical Holdings Corporation

Condensed Consolidated Statements of Changes in Equity and Income

(unaudited)

(in thousands)

	For the Three Months Ended March 31, 2024
		Total Stockholders’ Equity
	Common Stock Issued	Common Stock Par Value		Capital in Excess of Par		Retained Earnings		Accumulated Other Comprehensive Income		Total Stockholders’ Equity		Non-controlling Interests		Total Equity
Balance at December 31, 2023	128,369	$	128	$	493,413	$	751,856	$	42,907	$	1,288,304	$	259,414	$	1,547,718
Net income attributable to Select Medical Holdings Corporation						96,897				96,897				96,897
Net income attributable to non-controlling interests										—		17,845		17,845
Cash dividends declared for common stockholders ($0.125 per share)						(16,045)				(16,045)				(16,045)
Issuance of restricted stock	1	0		0						—				—
Forfeitures of unvested restricted stock	(12)	0		0		14				14				14
Vesting of restricted stock				11,596						11,596				11,596
Issuance of non-controlling interests										—		4,002		4,002
Distributions to and purchases of non-controlling interests				394						394		(10,900)		(10,506)
Redemption value adjustment on non-controlling interests						(1,901)				(1,901)				(1,901)
Other comprehensive loss								(11,977)		(11,977)				(11,977)
Balance at March 31, 2024	128,358	$	128	$	505,403	$	830,821	$	30,930	$	1,367,282	$	270,361	$	1,637,643

	For the Three Months Ended March 31, 2023
		Total Stockholders’ Equity
	Common Stock Issued	Common Stock Par Value		Capital in Excess of Par		Retained Earnings		Accumulated Other Comprehensive Income		Total Stockholders’ Equity		Non-controlling Interests		Total Equity
Balance at December 31, 2022	127,173	$	127	$	452,183	$	581,010	$	88,602	$	1,121,922	$	234,642	$	1,356,564
Net income attributable to Select Medical Holdings Corporation						70,805				70,805				70,805
Net income attributable to non-controlling interests										—		12,811		12,811
Cash dividends declared for common stockholders ($0.125 per share)						(15,897)				(15,897)				(15,897)
Issuance of restricted stock	3	0		0						—				—
Vesting of restricted stock				10,003						10,003				10,003
Issuance of non-controlling interests										—		2,731		2,731
Non-controlling interests acquired in business combination										—		3,877		3,877
Distributions to and purchases of non-controlling interests										—		(6,069)		(6,069)
Redemption value adjustment on non-controlling interests						(436)				(436)				(436)
Other comprehensive loss								(15,948)		(15,948)				(15,948)
Other				(1)		1				—				—
Balance at March 31, 2023	127,176	$	127	$	462,185	$	635,483	$	72,654	$	1,170,449	$	247,992	$	1,418,441

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

Select Medical Holdings Corporation

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

	For the Three Months Ended March 31,
	2023		2024
Operating activities
Net income	$	85,257	$	117,167
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	2,566		12,374
Depreciation and amortization	52,425		54,069
Provision for expected credit losses	429		854
Equity in earnings of unconsolidated subsidiaries	(8,556)		(10,421)
(Gain) loss on sale or disposal of assets	(7)		44
Stock compensation expense	10,181		11,610
Amortization of debt discount, premium, and issuance costs	565		750
Deferred income taxes	(2,601)		(6,891)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(55,397)		(195,308)
Other current assets	(11,742)		(9,611)
Other assets	3,659		2,363
Accounts payable	(4,564)		(5,718)
Accrued expenses	(20,775)		(37,971)
Net cash provided by (used in) operating activities	51,440		(66,689)
Investing activities
Business combinations, net of cash acquired	(397)		(5,405)
Purchases of property, equipment, and other assets	(58,885)		(52,517)
Investment in businesses	(9,800)		—
Proceeds from sale of assets and businesses	20		265
Net cash used in investing activities	(69,062)		(57,657)
Financing activities
Borrowings on revolving facilities	225,000		495,000
Payments on revolving facilities	(210,000)		(265,000)
Payments on term loans	—		(79,085)
Borrowings of other debt	21,448		17,728
Principal payments on other debt	(11,170)		(9,061)
Dividends paid to common stockholders	(15,897)		(16,045)
Decrease in overdrafts	(724)		(1,740)
Proceeds from issuance of non-controlling interests	2,731		4,002
Distributions to and purchases of non-controlling interests	(7,969)		(12,839)
Net cash provided by financing activities	3,419		132,960
Net increase (decrease) in cash and cash equivalents	(14,203)		8,614
Cash and cash equivalents at beginning of period	97,906		84,006
Cash and cash equivalents at end of period	$	83,703	$	92,620
Supplemental information
Cash paid for interest, excluding amounts received of $17,828 and $22,515 under the interest rate cap contract	$	84,531	$	88,834
Cash paid for taxes	336		604

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

SELECT MEDICAL HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1.                  Basis of Presentation

The unaudited condensed consolidated financial statements of Select Medical Holdings Corporation (“Holdings”) include the accounts of its wholly owned subsidiary, Select Medical Corporation (“Select”). Holdings conducts substantially all of its business through Select and its subsidiaries. Holdings, Select, and Select’s subsidiaries are collectively referred to as the “Company.” The unaudited condensed consolidated financial statements of the Company as of March 31, 2024, and for the three month periods ended March 31, 2023 and 2024, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting and the accounting principles generally accepted in the United States of America (“GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to the consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. All significant intercompany transactions and balances have been eliminated.

The results of operations for the three months ended March 31, 2024, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2024. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 22, 2024.

2.    Accounting Policies

Recent Accounting Guidance Not Yet Adopted

Segment Reporting

In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve disclosure of segment information so that investors can better understand an entity’s overall performance. The ASU requires entities to quantitatively disclose significant segment expenses that are regularly provided to the chief operating decision maker for each reportable segment, as well as the amount of other segment items for each reportable segment and a description of what the other segment items are comprised. Disclosure of multiple measures of profit or loss will be permitted by the ASU.

The ASU is effective for annual reporting periods beginning on or after December 15, 2023, and interim periods with fiscal years beginning after December 15, 2024; however, early adoption is permitted. The ASU is required to be applied retrospectively to all periods presented in the financial statements. The Company is currently reviewing the impact that ASU 2023-07 will have on the disclosures in our consolidated financial statements.

Income Taxes

In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve the transparency and decision usefulness of income tax disclosures. The ASU includes enhanced requirements on the rate reconciliation, including specific categories that must be disclosed, and provides a threshold over which reconciling items must be disclosed. The amendments in the update also require annual disclosure of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as any individual jurisdictions in which income taxes paid is greater than 5% of total income taxes paid.

The ASU is effective for annual periods beginning after December 15, 2024; however early adoption is permitted. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2023-09 will have to the disclosures in our consolidated financial statements.

8

Recently Adopted Accounting Guidance

Leases

In March 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-01, Leases (Topic 842): Common Control Arrangements, which requires companies to amortize leasehold improvements associated with related party leases under common control over the useful life of the leasehold improvement to the common control group. The ASU is effective for annual reporting periods beginning on or after December 15, 2023; however, early adoption is permitted. The ASU can either be applied prospectively or retrospectively.

The Company adopted this ASU using the prospective method of transition on January 1, 2024. There was not a material impact on the Company’s consolidated financial statements upon adoption.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.

3.     Credit Risk Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash balances and accounts receivable. The Company’s excess cash is held with large financial institutions. The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements.

Because of the diversity in the Company’s non-governmental third-party payor base, as well as their geographic dispersion, accounts receivable due from the Medicare program represent the Company’s only significant concentration of credit risk. Approximately 17% and 20% of the Company’s accounts receivable is due from Medicare at both December 31, 2023, and March 31, 2024, respectively.

4.     Redeemable Non-Controlling Interests

The ownership interests held by outside parties in subsidiaries, which include limited liability companies and limited partnerships, controlled by the Company are classified as non-controlling interests. Some of the Company’s non-controlling ownership interests consist of outside parties that have certain redemption rights that, if exercised, require the Company to purchase the parties’ ownership interests. These interests are classified and reported as redeemable non-controlling interests and have been adjusted to their redemption values, after the attribution of net income or loss.

The changes in redeemable non-controlling interests are as follows:

	Three Months Ended March 31,
	2023		2024
	(in thousands)
Balance as of January 1	$	34,043	$	26,297
Net income attributable to redeemable non-controlling interests	1,641		2,425
Distributions to redeemable non-controlling interests	(1,900)		(2,333)
Redemption value adjustment on redeemable non-controlling interests	436		1,901
Other	179		—
Balance as of March 31	$	34,399	$	28,290

5.     Variable Interest Entities

Certain states prohibit the “corporate practice of medicine,” which restricts the Company from owning medical practices which directly employ physicians or therapists and from exercising control over medical decisions by physicians and therapists. In these states, the Company enters into long-term management agreements with medical practices that are owned by licensed physicians or therapists, which, in turn, employ or contract with physicians or therapists who provide professional medical services. The management agreements provide for the Company to direct the transfer of ownership of the medical practices. Based on the provisions of the management agreements, the medical practices are variable interest entities for which the Company is the primary beneficiary.

9

As of December 31, 2023, and March 31, 2024, the total assets of the Company’s variable interest entities were $246.4 million and $263.7 million, respectively, and are principally comprised of accounts receivable. As of December 31, 2023, and March 31, 2024, the total liabilities of the Company’s variable interest entities were $84.3 million and $85.4 million, respectively, and are principally comprised of accounts payable and accrued expenses. These variable interest entities have obligations payable for services received under their management agreements with the Company of $161.8 million and $179.5 million as of December 31, 2023, and March 31, 2024, respectively. These intercompany balances are eliminated in consolidation.

6.     Leases

The Company’s total lease cost is as follows:

	Three Months Ended March 31, 2023						Three Months Ended March 31, 2024
	Unrelated Parties		Related Parties		Total		Unrelated Parties		Related Parties		Total
	(in thousands)
Operating lease cost	$	76,632	$	1,834	$	78,466	$	79,055	$	1,834	$	80,889
Finance lease cost:
Amortization of right-of-use assets	394		—		394		354		—		354
Interest on lease liabilities	320		—		320		304		—		304
Variable lease cost	15,761		84		15,845		17,076		—		17,076
Sublease income	(1,678)		—		(1,678)		(1,760)		—		(1,760)
Total lease cost	$	91,429	$	1,918	$	93,347	$	95,029	$	1,834	$	96,863

7.     Long-Term Debt and Notes Payable

As of March 31, 2024, the Company’s long-term debt and notes payable are as follows:

	Principal Outstanding		Unamortized Premium (Discount)		Unamortized Issuance Costs		Carrying Value		Fair Value
	(in thousands)
6.250% senior notes	$	1,225,000	$	14,041	$	(7,186)	$	1,231,855	$	1,226,531
Credit facilities:
Revolving facility	510,000		—		—		510,000		506,175
Term loan	2,013,400		(11,088)		(2,973)		1,999,339		2,015,917
Other debt, including finance leases	77,667		—		(46)		77,621		77,621
Total debt	$	3,826,067	$	2,953	$	(10,205)	$	3,818,815	$	3,826,244

Principal maturities of the Company’s long-term debt and notes payable are approximately as follows:

	2024		2025		2026		2027		2028		Thereafter		Total
	(in thousands)
6.250% senior notes	$	—	$	—	$	1,225,000	$	—	$	—	$	—	$	1,225,000
Credit facilities:
Revolving facility	—		—		—		510,000		—		—		510,000
Term loan	—		—		—		2,013,400		—		—		2,013,400
Other debt, including finance leases	58,155		3,151		2,461		1,941		1,620		10,339		77,667
Total debt	$	58,155	$	3,151	$	1,227,461	$	2,525,341	$	1,620	$	10,339	$	3,826,067

10

As of December 31, 2023, the Company’s long-term debt and notes payable are as follows:

	Principal Outstanding		Unamortized Premium (Discount)		Unamortized Issuance Costs		Carrying Value		Fair Value
	(in thousands)
6.250% senior notes	$	1,225,000	$	15,533	$	(7,937)	$	1,232,596	$	1,228,063
Credit facilities:
Revolving facility	280,000		—		—		280,000		278,600
Term loan	2,092,485		(12,040)		(3,229)		2,077,216		2,092,485
Other debt, including finance leases	68,255		—		(63)		68,192		68,192
Total debt	$	3,665,740	$	3,493	$	(11,229)	$	3,658,004	$	3,667,340

8.     Accrued and other liabilities

The following table sets forth the components of accrued and other liabilities on the Condensed Consolidated Balance Sheets:

	December 31, 2023		March 31, 2024
Accrued payroll	$	238,768	$	184,801
Accrued vacation	157,748		164,113
Accrued interest	32,472		14,438
Accrued other	297,663		292,587
Income taxes payable	1,499		30,552
Accrued and other liabilities	$	728,150	$	686,491

9.     Interest Rate Cap

The Company is subject to market risk exposure arising from changes in interest rates on its term loan, which bears interest at a rate which is indexed to one-month Term SOFR. The Company’s objective in using an interest rate derivative is to mitigate its exposure to increases in interest rates. The interest rate cap limits the Company’s exposure to increases in the variable rate index to 1.0% on $2.0 billion of principal outstanding under the term loan, as the interest rate cap provides for payments from the counterparty when interest rates rise above 1.0%. The interest rate cap has a $2.0 billion notional amount and is effective through September 30, 2024. The Company will pay a monthly premium for the interest rate cap over the term of the agreement. The annual premium is equal to 0.0916% of the notional amount, or approximately $1.8 million.

The interest rate cap has been designated as a cash flow hedge and is highly effective at offsetting the changes in cash outflows when the variable rate index exceeds 1.0%. Changes in the fair value of the interest rate cap, net of tax, are recognized in other comprehensive income and are reclassified out of accumulated other comprehensive income and into interest expense when the hedged interest obligations affect earnings.

The following table outlines the changes in accumulated other comprehensive income (loss), net of tax, during the periods presented:

	Three Months Ended March 31,
	2023		2024
	(in thousands)
Balance as of January 1	$	88,602	$	42,907
Gain (loss) on interest rate cap cash flow hedge	(2,696)		4,370
Amounts reclassified from accumulated other comprehensive income	(13,252)		(16,347)
Balance as of March 31	$	72,654	$	30,930

11

The effects on net income of amounts reclassified from accumulated other comprehensive income are as follows:

		Three Months Ended March 31,
Statement of Operations		2023		2024
	(in thousands)
Gains included in interest expense		$	17,552	$	21,509
Income tax expense		(4,300)		(5,162)
Amounts reclassified from accumulated other comprehensive income		$	13,252	$	16,347

The Company expects that approximately $40.7 million of estimated pre-tax gains will be reclassified from accumulated other comprehensive income into interest expense through the expiration of the interest rate cap on September 30, 2024.

Refer to Note 10 – Fair Value of Financial Instruments for information on the fair value of the Company’s interest rate cap contract and its balance sheet classification.

10.     Fair Value of Financial Instruments

Financial instruments which are measured at fair value, or for which a fair value is disclosed, are classified in the fair value hierarchy, as outlined below, on the basis of the observability of the inputs used in the fair value measurement:

•Level 1 – inputs are based upon quoted prices for identical instruments in active markets.

•Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data.

•Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the instrument.

The Company’s interest rate cap contract is recorded at its fair value in the condensed consolidated balance sheets on a recurring basis. The fair value of the interest rate cap contract is based upon a model-derived valuation using observable market inputs, such as interest rates and interest rate volatility, and the strike price.

Financial Instrument	Balance Sheet Classification	Level	December 31, 2023		March 31, 2024
Asset:			(in thousands)
Interest rate cap contract, current portion	Current portion of interest rate cap contract	Level 2	$	58,962	$	42,660

The Company does not measure its indebtedness at fair value in its condensed consolidated balance sheets. The fair value of the credit facilities is based on quoted market prices for this debt in the syndicated loan market. The fair value of the senior notes is based on quoted market prices. The carrying value of the Company’s other debt, as disclosed in Note 7 – Long-Term Debt and Notes Payable, approximates fair value.

		December 31, 2023				March 31, 2024
Financial Instrument	Level	Carrying Value		Fair Value		Carrying Value		Fair Value
		(in thousands)
6.250% senior notes	Level 2	$	1,232,596	$	1,228,063	$	1,231,855	$	1,226,531
Credit facilities:
Revolving facility	Level 2	280,000		278,600		510,000		506,175
Term loan	Level 2	2,077,216		2,092,485		1,999,339		2,015,917

The Company’s other financial instruments, which primarily consist of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value because of the short-term maturities of these instruments.

12

11.     Segment Information

The Company’s reportable segments consist of the critical illness recovery hospital segment, rehabilitation hospital segment, outpatient rehabilitation segment, and Concentra segment. Other activities include the Company’s corporate shared services, certain investments, and employee leasing services with non-consolidating subsidiaries.

The Company evaluates the performance of its segments based on Adjusted EBITDA. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, transaction costs associated with the Concentra separation, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. The Company has provided additional information regarding its reportable segments, such as total assets, which contributes to the understanding of the Company and provides useful information to the users of the consolidated financial statements.

The following tables summarize selected financial data for the Company’s reportable segments.

	Three Months Ended March 31,
	2023		2024
	(in thousands)
Revenue:
Critical illness recovery hospital	$	593,926	$	655,880
Rehabilitation hospital	231,462		265,700
Outpatient rehabilitation	295,903		303,158
Concentra	456,298		467,598
Other	87,391		96,473
Total Company	$	1,664,980	$	1,788,809
Adjusted EBITDA:
Critical illness recovery hospital	$	76,773	$	115,940
Rehabilitation hospital	47,216		61,400
Outpatient rehabilitation	30,199		24,928
Concentra	93,748		96,142
Other	(33,873)		(36,493)
Total Company	$	214,063	$	261,917
Total assets:
Critical illness recovery hospital	$	2,507,265	$	2,608,979
Rehabilitation hospital	1,203,069		1,233,828
Outpatient rehabilitation	1,397,823		1,423,740
Concentra	2,300,632		2,362,848
Other	290,947		228,868
Total Company	$	7,699,736	$	7,858,263
Purchases of property, equipment, and other assets:
Critical illness recovery hospital	$	23,658	$	15,941
Rehabilitation hospital	8,582		7,101
Outpatient rehabilitation	9,932		9,500
Concentra	14,400		17,231
Other	2,313		2,744
Total Company	$	58,885	$	52,517

13

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Adjusted EBITDA	$	76,773	$	47,216	$	30,199	$	93,748	$	(33,873)
Depreciation and amortization	(16,637)		(6,888)		(8,457)		(18,310)		(2,133)
Stock compensation expense	—		—		—		(178)		(10,003)
Income (loss) from operations	$	60,136	$	40,328	$	21,742	$	75,260	$	(46,009)	$	151,457
Equity in earnings of unconsolidated subsidiaries											8,556
Interest expense											(48,571)
Income before income taxes											$	111,442

	Three Months Ended March 31, 2024
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Adjusted EBITDA	$	115,940	$	61,400	$	24,928	$	96,142	$	(36,493)
Depreciation and amortization	(17,157)		(7,135)		(9,181)		(18,485)		(2,111)
Stock compensation expense	—		—		—		(166)		(11,444)
Concentra separation transaction costs(1)	—		—		—		(1,993)		(278)
Income (loss) from operations	$	98,783	$	54,265	$	15,747	$	75,498	$	(50,326)	$	193,967
Equity in earnings of unconsolidated subsidiaries											10,421
Interest expense											(50,763)
Income before income taxes											$	153,625

_______________________________________________________________________________

(1)    Concentra separation transaction costs represent incremental consulting, legal, and audit-related fees incurred in connection with the Company’s planned separation of the Concentra segment into a new, publicly traded company and are included within general and administrative expenses on the Condensed Consolidated Statements of Operations.

12.     Revenue from Contracts with Customers

The following tables disaggregate the Company’s revenue for the three months ended March 31, 2023 and 2024:

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Patient service revenue:
Medicare	$	229,383	$	110,055	$	45,801	$	243	$	—	$	385,482
Non-Medicare	363,305		109,925		231,985		454,598		—		1,159,813
Total patient services revenues	592,688		219,980		277,786		454,841		—		1,545,295
Other revenue	1,238		11,482		18,117		1,457		87,391		119,685
Total revenue	$	593,926	$	231,462	$	295,903	$	456,298	$	87,391	$	1,664,980

14

	Three Months Ended March 31, 2024
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Patient service revenue:
Medicare	$	226,261	$	126,386	$	45,841	$	266	$	—	$	398,754
Non-Medicare	428,666		126,577		239,613		465,601		—		1,260,457
Total patient services revenues	654,927		252,963		285,454		465,867		—		1,659,211
Other revenue	953		12,737		17,704		1,731		96,473		129,598
Total revenue	$	655,880	$	265,700	$	303,158	$	467,598	$	96,473	$	1,788,809

13.    Earnings per Share

The Company’s capital structure includes common stock and unvested restricted stock awards. To compute earnings per share (“EPS”), the Company applies the two-class method because the Company’s unvested restricted stock awards are participating securities which are entitled to participate equally with the Company’s common stock in undistributed earnings. Application of the Company’s two-class method is as follows:

(i)Net income attributable to the Company is reduced by the amount of dividends declared and by the contractual amount of dividends that must be paid for the current period for each class of stock. There were no contractual dividends paid for the three months ended March 31, 2023 and 2024.

(ii)The remaining undistributed net income of the Company is then equally allocated to its common stock and unvested restricted stock awards, as if all of the earnings for the period had been distributed. The total net income allocated to each security is determined by adding both distributed and undistributed net income for the period.

(iii)The net income allocated to each security is then divided by the weighted average number of outstanding shares for the period to determine the EPS for each security considered in the two-class method.

The following table sets forth the net income attributable to the Company, its common shares outstanding, and its participating securities outstanding.

	Basic and Diluted EPS
		Three Months Ended March 31,
		2023		2024
	(in thousands)
Net income		$	85,257	$	117,167
Less: net income attributable to non-controlling interests		14,452		20,270
Net income attributable to the Company		70,805		96,897
Less: Distributed and undistributed income attributable to participating securities		2,573		3,398
Distributed and undistributed income attributable to common shares		$	68,232	$	93,499

The following tables set forth the computation of EPS under the two-class method:

	Three Months Ended March 31,
	2023					2024
	Net Income Allocation		Shares(1)	Basic and Diluted EPS		Net Income Allocation		Shares(1)	Basic and Diluted EPS
	(in thousands, except for per share amounts)
Common shares	$	68,232	122,553	$	0.56	$	93,499	123,859	$	0.75
Participating securities	2,573		4,622	$	0.56	3,398		4,501	$	0.75
Total Company	$	70,805				$	96,897

_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

(1)    Represents the weighted average share count outstanding during the period.

15

14.    Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance coverages through a number of different programs that are dependent upon such factors as the state where the Company is operating and whether the operations are wholly owned or are operated through a joint venture. For the Company’s wholly owned hospital and outpatient clinic operations, the Company currently maintains insurance coverages under a combination of policies with a total annual aggregate limit of up to $37.0 million for professional malpractice liability insurance and $40.0 million for general liability insurance. For the Company’s Concentra center operations, the Company currently maintains insurance coverages under a combination of policies with a total annual aggregate limit of up to $29.0 million for professional malpractice liability insurance and $29.0 million for general liability insurance. The Company’s insurance for the professional liability coverage is written on a “claims-made” basis, and its commercial general liability coverage is maintained on an “occurrence” basis. These coverages apply after a self-insured retention limit is exceeded. For the Company’s joint venture operations, the Company has designed a separate insurance program that responds to the risks of specific joint ventures. Most of the Company’s joint ventures are insured under a master program with an annual aggregate limit of up to $80.0 million, subject to a sublimit aggregate ranging from $23.0 million to $33.0 million. The policies are generally written on a “claims-made” basis. Each of these programs has either a deductible or self-insured retention limit. The Company also maintains additional types of liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the applicable professional malpractice and general liability insurance policies, including workers compensation, property and casualty, directors and officers, cyber liability insurance, and employment practices liability insurance coverages. Our insurance policies generally are silent with respect to punitive damages so coverage is available to the extent insurable under the law of any applicable jurisdiction, and are subject to various deductibles and policy limits. The Company reviews its insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

Oklahoma City Investigation. On August 24, 2020, the Company and Select Specialty Hospital – Oklahoma City, Inc. (“SSH–Oklahoma City”) received civil investigative demands (“CIDs”) from the U.S. Attorney’s Office for the Western District of Oklahoma seeking responses to interrogatories and the production of various documents principally relating to the documentation, billing and reviews of medical services furnished to patients at SSH-Oklahoma City. The Company understands that the investigation arose from a qui tam lawsuit alleging billing fraud related to charges for respiratory therapy services at SSH–Oklahoma City and Select Specialty Hospital – Wichita, Inc. The Company has produced documents in response to the CIDs and is fully cooperating with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

16

Physical Therapy Billing. On October 7, 2021, the Company received a letter from a Trial Attorney at the U.S. Department of Justice, Civil Division, Commercial Litigation Branch, Fraud Section (“DOJ”) stating that the DOJ, in conjunction with the U.S. Department of Health and Human Services (“HHS”), is investigating the Company in connection with potential violations of the False Claims Act, 31 U.S.C. § 3729, et seq. The letter specified that the investigation relates to the Company’s billing for physical therapy services, and indicated that the DOJ would be requesting certain records from the Company. In October and December 2021, the DOJ requested, and the Company furnished, records relating to six of the Company’s outpatient therapy clinics in Florida. In 2022 and 2023, the DOJ requested certain data relating to all of the Company’s outpatient therapy clinics nationwide, and sought information about the Company’s ability to produce additional data relating to the physical therapy services furnished by the Company’s outpatient therapy clinics and Concentra. The Company has produced data and other documents requested by the DOJ and is fully cooperating on this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

California Department of Insurance Investigation. On February 5, 2024, Concentra received a subpoena from the California Department of Insurance relating to an investigation under the California Insurance Frauds Prevention Act (“IFPA”), Cal. Ins. Code § 1871.7 et seq., which allows a whistleblower to file a false claims lawsuit based on the submission of false or fraudulent claims to insurance companies. The subpoena seeks documentation relating mainly to Concentra’s billing and coding for physical therapy claims submitted to commercial insurers and workers compensation carriers located or doing business in California. The Company has produced data and other documents requested by the California Department of Insurance and is fully cooperating on this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

Perry Johnson & Associates, Inc. Data Breach. On November 10, 2023, Perry Johnson & Associates, Inc., a third-party vendor of health information technology solutions that provides medical transcription services (“PJ&A”), notified Concentra Health Services, Inc. (“Concentra”) that certain information related to particular Concentra patients was potentially affected by a cybersecurity event. In February 2024, Concentra sent notices to almost four million patients who may have been impacted by the data breach. During the first quarter of 2024, Concentra became aware of six putative class action lawsuits files against PJ&A and Concentra related to the data breach. The first was filed in the U.S. District Court for the Eastern District of Michigan on February 19, 2024 by Elliot Curry, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that he became the victim of identity theft as a result of the PJ&A data breach and that Concentra had lax data security policies. The second was filed in the U.S. District Court for the Eastern District of New York on February 21, 2024 by Tiffany Williams and Jo Joaquim, individually and on behalf of all others similarly situated. Plaintiffs alleged, among other things, that they face an immediate and heightened risk of identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard their private information. The third was filed in the U.S. District Court for the Eastern District of Missouri on February 26, 2024 by Stephen Tate, a.k.a. Steven Tate, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that he faces a heightened and imminent risk of identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard his private information. The fourth was filed in the U.S. District Court for the Eastern District of Michigan on February 26, 2024 by Eric Franczak, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that he faces a substantially increased risk of fraud and identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard his private information. The fifth was filed in the U.S. District Court for the Eastern District of Michigan on March 6, 2024 by Lazema Johnson, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that she faces a substantially increased risk of fraud and identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard her private information. The sixth was filed in the Superior Court of California, County of Los Angeles, on April 8, 2024 by Robert Valencia, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that he faces a substantially increased risk of fraud and identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard his private information. The Company is working with its cybersecurity risk insurance policy carrier and does not believe that the data breach or the lawsuits will have a material impact on its operations or financial performance. However, at this time, the Company is unable to predict the timing and outcome of these matters.

15.     Subsequent Events

On May 1, 2024, the Company’s Board of Directors declared a cash dividend of $0.125 per share. The dividend will be payable on or about May 30, 2024, to stockholders of record as of the close of business on May 16, 2024.

17

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read this discussion together with our unaudited condensed consolidated financial statements and accompanying notes.

Forward-Looking Statements

This report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words “may,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “plan,” “target,” “estimate,” “project,” “intend,” and similar expressions. These statements include, among others, statements regarding our expected business outlook, anticipated financial and operating results, including the potential impact of the COVID-19 pandemic on those financial and operating results, our business strategy and means to implement our strategy, our objectives, the amount and timing of capital expenditures, the likelihood of our success in expanding our business, financing plans, budgets, working capital needs, and sources of liquidity.

Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Important assumptions relating to the forward-looking statements include, among others, assumptions regarding our services, the expansion of our services, competitive conditions, and general economic conditions. These assumptions could prove inaccurate. Forward-looking statements also involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Many of these factors are beyond our ability to control or predict. Such factors include, but are not limited to, the following:

•changes in government reimbursement for our services and/or new payment policies may result in a reduction in revenue, an increase in costs, and a reduction in profitability;

•adverse economic conditions including an inflationary environment could cause us to continue to experience increases in the prices of labor and other costs of doing business resulting in a negative impact on our business, operating results, cash flows, and financial condition;

•shortages in qualified nurses, therapists, physicians, or other licensed providers, and/or the inability to attract or retain qualified healthcare professionals could limit our ability to staff our facilities;

•shortages in qualified health professionals could cause us to increase our dependence on contract labor, increase our efforts to recruit and train new employees, and expand upon our initiatives to retain existing staff, which could increase our operating costs significantly;

•public threats such as a global pandemic, or widespread outbreak of an infectious disease, similar to the COVID-19 pandemic, could negatively impact patient volumes and revenues, increase labor and other operating costs, disrupt global financial markets, and/or further legislative and regulatory actions which impact healthcare providers, including actions that may impact the Medicare program;

•the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause our revenue and profitability to decline;

•the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as “hospitals within hospitals” to qualify as hospitals separate from their host hospitals may cause our revenue and profitability to decline;

•a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;

•acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources, or expose us to unforeseen liabilities;

•our plans and expectations related to our acquisitions and our ability to realize anticipated synergies;

•failure to complete or achieve some or all the expected benefits of the potential separation of Concentra;

•private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability;

18

•the failure to maintain established relationships with the physicians in the areas we serve could reduce our revenue and profitability;

•competition may limit our ability to grow and result in a decrease in our revenue and profitability;

•the loss of key members of our management team could significantly disrupt our operations;

•the effect of claims asserted against us could subject us to substantial uninsured liabilities;

•a security breach of our or our third-party vendors’ information technology systems may subject us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act; and

•other factors discussed from time to time in our filings with the SEC, including factors discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023.

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose to securities analysts any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any securities analyst irrespective of the content of the statement or report. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

Overview

 We began operations in 1997 and, based on number of facilities, are one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. As of March 31, 2024, we had operations in 46 states and the District of Columbia. We operated 107 critical illness recovery hospitals in 28 states, 33 rehabilitation hospitals in 13 states, 1,922 outpatient rehabilitation clinics in 39 states and the District of Columbia, 547 occupational health centers in 41 states, and 151 onsite clinics at employer worksites.

Our reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. We had revenue of $1,788.8 million for the three months ended March 31, 2024. Of this total, we earned approximately 37% of our revenue from our critical illness recovery hospital segment, approximately 15% from our rehabilitation hospital segment, approximately 17% from our outpatient rehabilitation segment, and approximately 26% from our Concentra segment. Our critical illness recovery hospital segment consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs, and our rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to our critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. Our outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. Our Concentra segment consists of occupational health centers that provide workers’ compensation injury care, physical therapy, and consumer health services as well as onsite clinics located at employer worksites that deliver occupational health services.

On January 3, 2024, the Company announced its intention to separate Concentra, with the intention to create a new, publicly traded company by the end of the fiscal year 2024. On February 27, 2024, we received a private letter ruling from the U.S. Internal Revenue Service to the effect that the distribution of Concentra’s common stock to Select and our stockholders will be tax-free for U.S federal income tax purposes. On March 18, 2024, Concentra confidentially submitted a draft registration statement on From S-1 with the SEC relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to occur after the SEC completes its review process, subject to market and other conditions. There can be no assurance regarding the ultimate timing of the planned separation or that such separation will be completed.

19

Impact of the Change Healthcare Cybersecurity Incident

On February 22, 2024, UnitedHealth Group Incorporated indicated in a Form 8-K filing, that a cyber security threat actor had gained access to some of its Change Healthcare information technology systems. Upon receiving notification of the incident, we severed connectivity with all Change Healthcare-related systems and we are not aware of any impact on our own information technology systems. However, as a result of the incident, certain of our patient billing and collections processes were disrupted and alternative platforms needed to be enabled to resume normal patient billing and collections operations. The Company began to reconnect to certain applications maintained by Change Healthcare in late March 2024.

As of March 31, 2024, the impact on the Company was primarily a decrease in cash flows from operations, as further described in Liquidity and Capital Resources, driven by an increase in accounts receivable that is expected to return to more normalized levels in the second and third quarters of 2024. Although we utilized borrowing capacity under our revolving facility to fund the temporary shortfall in cash flows from operations, the Company continues to maintain strong liquidity and to date, the Change Healthcare incident has not had a material impact on the Company’s results of operations or financial condition.

Non-GAAP Measure

We believe that the presentation of Adjusted EBITDA, as defined below, is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of our segments. Adjusted EBITDA is not a measure of financial performance under GAAP. Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, transaction costs associated with the Concentra separation, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. We will refer to Adjusted EBITDA throughout the remainder of Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following table reconciles net income and income from operations to Adjusted EBITDA and should be referenced when we discuss Adjusted EBITDA:

		Three Months Ended March 31,
		2023		2024
	(in thousands)
Net income		$	85,257	$	117,167
Income tax expense		26,185		36,458
Interest expense		48,571		50,763
Equity in earnings of unconsolidated subsidiaries		(8,556)		(10,421)
Income from operations		151,457		193,967
Stock compensation expense:
Included in general and administrative		8,405		9,682
Included in cost of services		1,776		1,928
Depreciation and amortization		52,425		54,069
Concentra separation transaction costs(1)		—		2,271
Adjusted EBITDA		$	214,063	$	261,917

_______________________________________________________________________________

(1)    Concentra separation transaction costs represent incremental consulting, legal, and audit-related fees incurred in connection with the Company’s planned separation of the Concentra segment into a new, publicly traded company and are included within general and administrative expenses on the Condensed Consolidated Statements of Operations.

20

Summary Financial Results

Three Months Ended March 31, 2024

The following tables reconcile our segment performance measures to our consolidated operating results:

	Three Months Ended March 31, 2024
	Critical Illness Recovery Hospital			Rehabilitation Hospital			Outpatient Rehabilitation			Concentra			Other		Total
	(in thousands)
Revenue	$	655,880		$	265,700		$	303,158		$	467,598		$	96,473	$	1,788,809
Operating expenses	(541,940)			(204,300)			(278,230)			(373,899)			(144,688)		(1,543,057)
Depreciation and amortization	(17,157)			(7,135)			(9,181)			(18,485)			(2,111)		(54,069)
Other operating income	2,000			—			—			284			—		2,284
Income (loss) from operations	$	98,783		$	54,265		$	15,747		$	75,498		$	(50,326)	$	193,967
Depreciation and amortization	17,157			7,135			9,181			18,485			2,111		54,069
Concentra separation transaction costs	—			—			—			1,993			278		2,271
Stock compensation expense	—			—			—			166			11,444		11,610
Adjusted EBITDA	$	115,940		$	61,400		$	24,928		$	96,142		$	(36,493)	$	261,917
Adjusted EBITDA margin	17.7		%	23.1		%	8.2		%	20.6		%	N/M		14.6		%

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital			Rehabilitation Hospital			Outpatient Rehabilitation			Concentra			Other		Total
	(in thousands)
Revenue	$	593,926		$	231,462		$	295,903		$	456,298		$	87,391	$	1,664,980
Operating expenses	(517,153)			(184,246)			(265,704)			(362,728)			(131,267)		(1,461,098)
Depreciation and amortization	(16,637)			(6,888)			(8,457)			(18,310)			(2,133)		(52,425)
Income (loss) from operations	$	60,136		$	40,328		$	21,742		$	75,260		$	(46,009)	$	151,457
Depreciation and amortization	16,637			6,888			8,457			18,310			2,133		52,425
Stock compensation expense	—			—			—			178			10,003		10,181
Adjusted EBITDA	$	76,773		$	47,216		$	30,199		$	93,748		$	(33,873)	$	214,063
Adjusted EBITDA margin	12.9		%	20.4		%	10.2		%	20.5		%	N/M		12.9		%

Net income was $117.2 million for the three months ended March 31, 2024, compared to $85.3 million for the three months ended March 31, 2023.

The following table summarizes the changes in our segment performance measures for the three months ended March 31, 2024, compared to the three months ended March 31, 2023:

	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
Change in revenue	10.4	%	14.8	%	2.5	%	2.5	%	10.4	%	7.4	%
Change in income from operations	64.3	%	34.6	%	(27.6)	%	0.3	%	N/M		28.1	%
Change in Adjusted EBITDA	51.0	%	30.0	%	(17.5)	%	2.6	%	N/M		22.4	%

_______________________________________________________________________________

N/M —     Not meaningful.

21

Regulatory Changes

Our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 22, 2024, contains a detailed discussion of the regulations that affect our business in Part I — Business — Government Regulations. The following is a discussion of some of the more significant healthcare regulatory changes that have affected our financial performance in the periods covered by this report, or are likely to affect our financial performance and financial condition in the future. The information below should be read in conjunction with the more detailed discussion of regulations contained in our Form 10-K.

Medicare Reimbursement

The Medicare program reimburses healthcare providers for services furnished to Medicare beneficiaries, which are generally persons age 65 and older, those who are chronically disabled, and those suffering from end stage renal disease. The program is governed by the Social Security Act of 1965 and is administered primarily by the Department of Health and Human Services (“HHS”) and CMS. Revenue generated directly from the Medicare program represented approximately 22% and 23% of our revenue for the three months ended March 31, 2024, and for the year ended December 31, 2023, respectively.

Federal Health Care Program Changes in Response to the COVID-19 Pandemic

On January 31, 2020, HHS declared a public health emergency under section 319 of the Public Health Service Act, 42 U.S.C. § 247d, in response to the COVID-19 outbreak in the United States. The HHS Secretary renewed the public health emergency determination for subsequent 90-day periods through May 11, 2023, the end of the public health emergency. The COVID-19 national emergency that was declared by President Trump on March 13, 2020, which was separate from the public health emergency, ended on April 10, 2023 when H.R.J. Res. 7 was signed into law.

As a result of the COVID-19 national emergency, the HHS Secretary authorized the waiver or modification of certain requirements under Medicare, Medicaid, and the Children’s Health Insurance Program (“CHIP”) pursuant to section 1135 of the Social Security Act. Under this authority, CMS issued a number of blanket waivers that excused health care providers or suppliers from specific program requirements. Our Annual Report on Form 10-K for the year ended December 31, 2023, contains a detailed discussion of the federal health care program changes made in response to the COVID-19 pandemic, including these COVID-19 waivers, in Part II — Management’s Discussion and Analysis of Financial Condition and Results of Operations — Regulatory Changes. Most of these COVID-19 waivers, including the waiver of the IRF 60% Rule and the waiver of Medicare statutory requirements regarding site neutral payments to long-term care hospitals (“LTCHs”), ended when the public health emergency expired on May 11, 2023. However, LTCHs are exempt from the greater-than-25-day average length of stay requirement for all cost reporting periods that include the COVID-19 public health emergency period. As a result, LTCH cost reporting periods that started prior to May 11, 2023, will continue to be exempt for the remainder of that cost reporting year. However, LTCH cost reporting periods that begin on or after May 11, 2023, must comply with the greater-than-25-day average length of stay requirement.

In addition, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act and related legislation temporarily suspended the 2% cut to Medicare payments due to sequestration from May 1, 2020, through March 31, 2022, and reduced the sequestration adjustment from 2% to 1% from April 1 through June 30, 2022. The full 2% reduction resumed on July 1, 2022. To pay for this relief, Congress increased the sequestration cut to Medicare payments to 2.25% for the first six months of fiscal year 2030 and to 3% for the final six months of fiscal year 2030. Additionally, an across-the-board 4% payment cut required to take effect in January 2022 due to the American Rescue Plan from the FY 2022 Statutory Pay-As-You-Go (“PAYGO”) scorecard was deferred by Congress until 2025.

The CARES Act and related legislation also provided more than $178 billion in appropriations for the Public Health and Social Services Emergency Fund, also known as the Provider Relief Fund, to be used for preventing, preparing, and responding to COVID-19 and for reimbursing “eligible health care providers for health care related expenses or lost revenues that are attributable to coronavirus.” HHS began distributing these funds to providers in April 2020. Recipients of payments were required to report data to HHS on the use of the funds via an online portal by specific deadlines established by HHS based on the date of the payment. All recipients of funds are subject to audit by HHS, the HHS OIG, or the Pandemic Response Accountability Committee. Audits may include examination of the accuracy of the data providers submitted to HHS in their applications for payments. Additional distributions are not expected and as a result, the Company does not expect to recognize additional income associated with these funds in the future.

22

Medicare Reimbursement of LTCH Services

The following is a summary of significant regulatory changes to the Medicare prospective payment system for our critical illness recovery hospitals, which are certified by Medicare as LTCHs, which have affected our results of operations, as well as the policies and payment rates that may affect our future results of operations. Medicare payments to our critical illness recovery hospitals are made in accordance with the long-term care hospital prospective payment system (“LTCH-PPS”).

Fiscal Year 2023. On August 10, 2022, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2023 (affecting discharges and cost reporting periods beginning on or after October 1, 2022, through September 30, 2023). Certain errors in the final rule were corrected in documents published November 4, 2022, and December 13, 2022. The standard federal rate for fiscal year 2023 was set at $46,433, an increase from the standard federal rate applicable during fiscal year 2022 of $44,714. The update to the standard federal rate for fiscal year 2023 included a market basket increase of 4.1%, less a productivity adjustment of 0.3%. The standard federal rate also included an area wage budget neutrality factor of 1.0004304. As a result of the CARES Act, all LTCH cases were paid at the standard federal rate during the public health emergency. When the public health emergency ended on May 11, 2023, CMS returned to using the site-neutral payment rate for reimbursement of cases that do not meet the LTCH patient criteria. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS was set at $38,518, an increase from the fixed-loss amount in the 2022 fiscal year of $33,015. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate was set at $38,788, an increase from the fixed-loss amount in the 2022 fiscal year of $30,988.

Fiscal Year 2024. On August 28, 2023, CMS published the final rule updating policies and payment rates for the LTCH-PPS for fiscal year 2024 (affecting discharges and cost reporting periods beginning on or after October 1, 2023, through September 30, 2024). Certain errors in the final rule were corrected in a document published on October 4, 2023. The standard federal rate for fiscal year 2024 is $48,117, an increase from the standard federal rate applicable during fiscal year 2023 of $46,433. The update to the standard federal rate for fiscal year 2024 includes a market basket increase of 3.5%, less a productivity adjustment of 0.2%. The standard federal rate also includes an area wage budget neutrality factor of 1.0031599. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS is $59,873, an increase from the fixed-loss amount in the 2023 fiscal year of $38,518. The fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate is $42,750, an increase from the fixed-loss amount in the 2023 fiscal year of $38,788.

Fiscal Year 2025. On April 10, 2024, CMS released a display copy of the proposed rule to update policies and payment rates for the LTCH-PPS for fiscal year 2025 (affecting discharges and cost reporting periods beginning on or after October 1, 2024, through September 30, 2025). CMS is expected to issue the final rule in August or shortly thereafter. The proposed standard federal rate for fiscal year 2025 is $49,263, an increase from the standard federal rate applicable during fiscal year 2024 of $48,117. The proposed update to the standard federal rate for fiscal year 2025 includes a market basket increase of 3.2%, less a productivity adjustment of 0.4%. The proposed standard federal rate also includes an area wage budget neutrality factor of 0.9959347. The proposed fixed-loss amount for high cost outlier cases paid under LTCH-PPS is $90,921, an increase from the fixed-loss amount in the 2024 fiscal year of $59,873. The proposed fixed-loss amount for high cost outlier cases paid under the site-neutral payment rate is $49,237, an increase from the fixed-loss amount in the 2024 fiscal year of $42,750.

Medicare Reimbursement of IRF Services

The following is a summary of significant regulatory changes to the Medicare prospective payment system for our rehabilitation hospitals, which are certified by Medicare as IRFs, which have affected our results of operations, as well as the policies and payment rates that may affect our future results of operations. Medicare payments to our rehabilitation hospitals are made in accordance with the inpatient rehabilitation facility prospective payment system (“IRF-PPS”).

Fiscal Year 2023. On August 1, 2022, CMS published the final rule updating policies and payment rates for the IRF-PPS for fiscal year 2023 (affecting discharges and cost reporting periods beginning on or after October 1, 2022, through September 30, 2023). The standard payment conversion factor for discharges for fiscal year 2023 was set at $17,878, an increase from the standard payment conversion factor applicable during fiscal year 2022 of $17,240. The update to the standard payment conversion factor for fiscal year 2023 included a market basket increase of 4.2%, less a productivity adjustment of 0.3%. CMS increased the outlier threshold amount for fiscal year 2023 to $12,526 from $9,491 established in the final rule for fiscal year 2022.

23

Fiscal Year 2024. On August 2, 2023, CMS published the final rule to update policies and payment rates for the IRF-PPS for fiscal year 2024 (affecting discharges and cost reporting periods beginning on or after October 1, 2023, through September 30, 2024). Certain errors in the final rule were corrected in a document published on October 4, 2023. The standard payment conversion factor for discharges for fiscal year 2024 was set at $18,541, an increase from the standard payment conversion factor applicable during fiscal year 2023 of $17,878. The update to the standard payment conversion factor for fiscal year 2024 included a market basket increase of 3.6%, less a productivity adjustment of 0.2%. CMS decreased the outlier threshold amount for fiscal year 2024 to $10,423 from $12,526 established in the final rule for fiscal year 2023.

Fiscal Year 2025. On March 29, 2024, CMS published a proposed rule to update policies and payment rates for the IRF-PPS for fiscal year 2025 (affecting discharges and cost reporting periods beginning on or after October 1, 2024, through September 30, 2025). The standard payment conversion factor for discharges for fiscal year 2025 would be set at $18,872, an increase from the standard payment conversion factor applicable during fiscal year 2024 of $18,541. The update to the standard payment conversion factor for fiscal year 2025, if adopted, would include a market basket increase of 3.2%, less a productivity adjustment of 0.4%. CMS proposed to increase the outlier threshold amount for fiscal year 2025 to $12,158 from $10,423 established in the final rule for fiscal year 2024.

Medicare Reimbursement of Outpatient Rehabilitation Clinic Services

Our Annual Report on Form 10-K for the year ended December 31, 2023 contains a detailed discussion of Medicare reimbursement that affects our outpatient rehabilitation clinic operations in Part I — Business — Government Regulations and in Part II — Management’s Discussion and Analysis of Financial Condition and Results of Operations — Regulatory Changes. Outpatient rehabilitation providers enroll in Medicare as a rehabilitation agency, a clinic, or a public health agency. The Medicare program reimburses outpatient rehabilitation providers based on the Medicare physician fee schedule.

For calendar years 2021 and 2022, CMS’s expected decreases in Medicare reimbursement were mostly offset by one-time increases in payments as a result of other legislation passed by Congress. Payments under the 2023 MPFS physician fee schedule decreased by 2%, and for calendar year 2024, final CMS policies resulted in an approximate 3% decrease in Medicare payments for the therapy specialty. On March 9, 2024, President Biden signed into law the Consolidated Appropriations Act, 2024, which mitigated Medicare physician payment cuts by 1.68%, resulting in a lower, 1.69% cut to payments. The full 3.37% cut was applied to payments for services provided between January 1, 2024 and the March 9, 2024 effective date. The Consolidated Appropriations Act, 2024 also extends the Medicare physician work geographic index floor through December 31, 2024. The steps Congress has taken to reduce the cuts to Medicare physician payments for the remainder of 2024 are temporary and will not carry over into 2025.

Modifiers to Identify Services of Physical Therapy Assistants or Occupational Therapy Assistants

Our Annual Report on Form 10-K for the year ended December 31, 2023, contains a detailed discussion of Medicare regulations concerning services provided by physical therapy assistants and occupational therapy assistants in Part I — Business — Government Regulations and in Part II — Management’s Discussion and Analysis of Financial Condition and Results of Operations — Regulatory Changes. There have been no significant updates to these regulations subsequently.

24

Operating Statistics

The following table sets forth operating statistics for each of our segments for the periods presented. The operating statistics reflect data for the period of time we managed these operations. Our operating statistics include metrics we believe provide relevant insight about the number of facilities we operate, volume of services we provide to our patients, and average payment rates for services we provide. These metrics are utilized by management to monitor trends and performance in our businesses and therefore may be important to investors because management may assess our performance based in part on such metrics. Other healthcare providers may present similar statistics, and these statistics are susceptible to varying definitions. Our statistics as presented may not be comparable to other similarly titled statistics of other companies.

	Three Months Ended March 31,
	2023			2024
Critical illness recovery hospital data:
Number of consolidated hospitals—start of period(1)	103			107
Number of hospitals acquired	—			—
Number of hospital start-ups	2			—
Number of hospitals closed/sold	—			—
Number of consolidated hospitals—end of period(1)	105			107
Available licensed beds(3)	4,440			4,534
Admissions(3)(4)	9,438			9,529
Patient days(3)(5)	286,746			294,622
Average length of stay (days)(3)(6)	30			31
Revenue per patient day(3)(7)	$	2,058		$	2,219
Occupancy rate(3)(8)	72		%	71		%
Percent patient days—Medicare(3)(9)	39		%	36		%
Rehabilitation hospital data:
Number of consolidated hospitals—start of period(1)	20			21
Number of hospitals acquired	—			—
Number of hospital start-ups	—			—
Number of hospitals closed/sold	—			—
Number of consolidated hospitals—end of period(1)	20			21
Number of unconsolidated hospitals managed—end of period(2)	12			12
Total number of hospitals (all)—end of period	32			33
Available licensed beds(3)	1,413			1,479
Admissions(3)(4)	7,620			8,275
Patient days(3)(5)	107,910			116,844
Average length of stay (days)(3)(6)	14			14
Revenue per patient day(3)(7)	$	1,969		$	2,096
Occupancy rate(3)(8)	86		%	87		%
Percent patient days—Medicare(3)(9)	49		%	49		%
Outpatient rehabilitation data:
Number of consolidated clinics—start of period	1,622			1,633
Number of clinics acquired	9			1
Number of clinic start-ups	12			3
Number of clinics closed/sold	(11)			(13)
Number of consolidated clinics—end of period	1,632			1,624
Number of unconsolidated clinics managed—end of period	304			298
Total number of clinics (all)—end of period	1,936			1,922
Number of visits(3)(10)	2,636,770			2,735,126
Revenue per visit(3)(11)	$	101		$	99

25

	Three Months Ended March 31,
	2023		2024
Concentra data:
Number of consolidated centers—start of period	540		544
Number of centers acquired	—		2
Number of center start-ups	—		1
Number of centers closed/sold	(1)		—
Number of consolidated centers—end of period	539		547
Number of onsite clinics operated—end of period	140		151
Number of visits(3)(10)	3,217,945		3,155,655
Revenue per visit(3)(11)	$	133	$	139

_______________________________________________________________________________

(1)Represents the number of hospitals included in our consolidated financial results at the end of each period presented.

(2)Represents the number of hospitals which are managed by us at the end of each period presented. We have minority ownership interests in these businesses.

(3)Data excludes locations managed by the Company. For purposes of our Concentra segment, onsite clinics are excluded.

(4)Represents the number of patients admitted to our hospitals during the periods presented.

(5)Each patient day represents one patient occupying one bed for one day during the periods presented.

(6)Represents the average number of days in which patients were admitted to our hospitals. Average length of stay is calculated by dividing the number of patient days, as presented above, by the number of patients discharged from our hospitals during the periods presented.

(7)Represents the average amount of revenue recognized for each patient day. Revenue per patient day is calculated by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at our hospitals, by the total number of patient days.

(8)Represents the portion of our hospitals being utilized for patient care during the periods presented. Occupancy rate is calculated using the number of patient days, as presented above, divided by the total number of bed days available during the period. Bed days available is derived by adding the daily number of available licensed beds for each of the periods presented.

(9)Represents the portion of our patient days which are paid by Medicare. The Medicare patient day percentage is calculated by dividing the total number of patient days which are paid by Medicare by the total number of patient days, as presented above.

(10)Represents the number of visits in which patients were treated at our outpatient rehabilitation clinics and Concentra centers during the periods presented.

(11)Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits.

26

Results of Operations

The following table outlines selected operating data as a percentage of revenue for the periods indicated:

	Three Months Ended March 31,
	2023		2024
Revenue	100.0	%	100.0	%
Costs and expenses:
Cost of services, exclusive of depreciation and amortization(1)	85.2		83.6
General and administrative	2.5		2.7
Depreciation and amortization	3.2		3.0
Total costs and expenses	90.9		89.3
Other operating income	—		0.1
Income from operations	9.1		10.8
Equity in earnings of unconsolidated subsidiaries	0.5		0.6
Interest expense	(2.9)		(2.8)
Income before income taxes	6.7		8.6
Income tax expense	1.6		2.0
Net income	5.1		6.6
Net income attributable to non-controlling interests	0.8		1.2
Net income attributable to Select Medical Holdings Corporation	4.3	%	5.4	%

_______________________________________________________________________________

(1)Cost of services includes salaries, wages and benefits, operating supplies, lease and rent expense, and other operating costs.

27

The following table summarizes selected financial data by segment for the periods indicated:

		Three Months Ended March 31,
		2023			2024			% Change
	(in thousands, except percentages)
Revenue:
Critical illness recovery hospital		$	593,926		$	655,880		10.4	%
Rehabilitation hospital		231,462			265,700			14.8
Outpatient rehabilitation		295,903			303,158			2.5
Concentra		456,298			467,598			2.5
Other(1)		87,391			96,473			10.4
Total Company		$	1,664,980		$	1,788,809		7.4	%
Income (loss) from operations:
Critical illness recovery hospital		$	60,136		$	98,783		64.3	%
Rehabilitation hospital		40,328			54,265			34.6
Outpatient rehabilitation		21,742			15,747			(27.6)
Concentra		75,260			75,498			0.3
Other(1)		(46,009)			(50,326)			N/M
Total Company		$	151,457		$	193,967		28.1	%
Adjusted EBITDA:
Critical illness recovery hospital		$	76,773		$	115,940		51.0	%
Rehabilitation hospital		47,216			61,400			30.0
Outpatient rehabilitation		30,199			24,928			(17.5)
Concentra		93,748			96,142			2.6
Other(1)		(33,873)			(36,493)			N/M
Total Company		$	214,063		$	261,917		22.4	%
Adjusted EBITDA margins:
Critical illness recovery hospital		12.9		%	17.7		%
Rehabilitation hospital		20.4			23.1
Outpatient rehabilitation		10.2			8.2
Concentra		20.5			20.6
Other(1)		N/M			N/M
Total Company		12.9		%	14.6		%
Total assets:
Critical illness recovery hospital		$	2,507,265		$	2,608,979
Rehabilitation hospital		1,203,069			1,233,828
Outpatient rehabilitation		1,397,823			1,423,740
Concentra		2,300,632			2,362,848
Other(1)		290,947			228,868
Total Company		$	7,699,736		$	7,858,263
Purchases of property, equipment, and other assets:
Critical illness recovery hospital		$	23,658		$	15,941
Rehabilitation hospital		8,582			7,101
Outpatient rehabilitation		9,932			9,500
Concentra		14,400			17,231
Other(1)		2,313			2,744
Total Company		$	58,885		$	52,517

_______________________________________________________________________________

(1)    Other includes our corporate administration and shared services, as well as employee leasing services with our non-consolidating subsidiaries. Total assets include certain non-consolidating joint ventures and minority investments in other healthcare related businesses.

N/M — Not meaningful.

28

Three Months Ended March 31, 2024, Compared to Three Months Ended March 31, 2023

For the three months ended March 31, 2024, we had revenue of $1,788.8 million and income from operations of $194.0 million, respectively, as compared to revenue of $1,665.0 million and income from operations of $151.5 million for the three months ended March 31, 2023. For the three months ended March 31, 2024, Adjusted EBITDA was $261.9 million, with an Adjusted EBITDA margin of 14.6%, as compared to Adjusted EBITDA of $214.1 million and an Adjusted EBITDA margin of 12.9% for the three months ended March 31, 2023, respectively.

A significant contributor to the improvement in our financial performance for the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, was the increase in revenue in our Critical Illness Recovery Hospital and Rehabilitation Hospital segments, as discussed below under “Revenue.”

Revenue

Critical Illness Recovery Hospital Segment.   Revenue increased 10.4% to $655.9 million for the three months ended March 31, 2024, compared to $593.9 million for the three months ended March 31, 2023. Revenue per patient day increased 7.8% to $2,219 for the three months ended March 31, 2024, compared to $2,058 for the three months ended March 31, 2023. Our patient days increased 2.7% to 294,622 for the three months ended March 31, 2024, compared to 286,746 days for the three months ended March 31, 2023. Occupancy in our critical illness recovery hospitals was 71% and 72% for the three months ended March 31, 2024 and 2023, respectively.

Rehabilitation Hospital Segment.   Revenue increased 14.8% to $265.7 million for the three months ended March 31, 2024, compared to $231.5 million for the three months ended March 31, 2023. Our patient days increased 8.3% to 116,844 days for the three months ended March 31, 2024, compared to 107,910 days for the three months ended March 31, 2023. Revenue per patient day increased 6.4% to $2,096 for the three months ended March 31, 2024, compared to $1,969 for the three months ended March 31, 2023. Occupancy in our rehabilitation hospitals was 87% and 86% for the three months ended March 31, 2024 and 2023, respectively.

Outpatient Rehabilitation Segment.   Revenue increased 2.5% to $303.2 million for the three months ended March 31, 2024, compared to $295.9 million for the three months ended March 31, 2023. The increase in revenue was attributable to patient visits, which increased 3.7% to 2,735,126 visits for the three months ended March 31, 2024, compared to 2,636,770 visits for the three months ended March 31, 2023. Our revenue per visit was $99 for the three months ended March 31, 2024, compared to $101 for the three months ended March 31, 2023, principally due to a decrease in Medicare reimbursement and changes in payor mix.

Concentra Segment.   Revenue increased 2.5% to $467.6 million for the three months ended March 31, 2024, compared to $456.3 million for the three months ended March 31, 2023. The increase in revenue was attributable to revenue per visit, which increased 4.5% to $139 for the three months ended March 31, 2024, compared to $133 for the three months ended March 31, 2023. Our patient visits were 3,155,655 for the three months ended March 31, 2024, compared to 3,217,945 visits for the three months ended March 31, 2023.

Operating Expenses

Our operating expenses consist principally of cost of services and general and administrative expenses. Our operating expenses were $1,543.1 million, or 86.3% of revenue, for the three months ended March 31, 2024, compared to $1,461.1 million, or 87.7% of revenue, for the three months ended March 31, 2023. Our cost of services, a major component of which is labor expense, was $1,494.6 million, or 83.6% of revenue, for the three months ended March 31, 2024, compared to $1,418.8 million, or 85.2% of revenue, for the three months ended March 31, 2023. The decrease in our operating expenses relative to our revenue was principally attributable to an increase in revenue in our Critical Illness Recovery Hospital and Rehabilitation Hospital segments. General and administrative expenses were $48.4 million, or 2.7% of revenue, for the three months ended March 31, 2024, compared to $42.3 million, or 2.5% of revenue, for the three months ended March 31, 2023. General and administrative expenses included $2.3 million of Concentra separation transaction costs for the three months ended March 31, 2024.

Other Operating Income

For the three months ended March 31, 2024, we had other operating income of $2.3 million. The other operating income for the three months ended March 31, 2024 is principally included within the operating results of our Critical Illness Recovery Hospital segment.

29

Adjusted EBITDA

Critical Illness Recovery Hospital Segment.  Adjusted EBITDA increased 51.0% to $115.9 million for the three months ended March 31, 2024, compared to $76.8 million for the three months ended March 31, 2023. Our Adjusted EBITDA margin for the critical illness recovery hospital segment was 17.7% for the three months ended March 31, 2024, compared to 12.9% for the three months ended March 31, 2023. The increases in our Adjusted EBITDA and Adjusted EBITDA margin during the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, were principally due to an increase in revenue. Additionally, our total contract labor costs decreased by approximately 20% during the year ended March 31, 2024, as compared to the year ended March 31, 2023, which was driven by an approximate 20% decrease in utilization of contract registered nurses and an approximate 7% decrease in the rate per hour for contract registered nurses.

Rehabilitation Hospital Segment.   Adjusted EBITDA increased 30.0% to $61.4 million for the three months ended March 31, 2024, compared to $47.2 million for the three months ended March 31, 2023. Our Adjusted EBITDA margin for the rehabilitation hospital segment was 23.1% for the three months ended March 31, 2024, compared to 20.4% for the three months ended March 31, 2023. The increases in our Adjusted EBITDA and Adjusted EBITDA margin for the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, were principally attributable to an increase in revenue.

Outpatient Rehabilitation Segment.   Adjusted EBITDA was $24.9 million for the three months ended March 31, 2024, compared to $30.2 million for the three months ended March 31, 2023. Our Adjusted EBITDA margin for the outpatient rehabilitation segment was 8.2% for the three months ended March 31, 2024, compared to 10.2% for the three months ended March 31, 2023. The decreases in our Adjusted EBITDA and Adjusted EBITDA margin for the three months ended March 31, 2024, as compared to the three months ended March 31, 2023, were principally attributable due to higher labor costs, partially offset by an increase in revenue.

Concentra Segment.   Adjusted EBITDA increased 2.6% to $96.1 million for the three months ended March 31, 2024, compared to $93.7 million for the three months ended March 31, 2023. Our Adjusted EBITDA margin for the Concentra segment was 20.6% for the three months ended March 31, 2024, compared to 20.5% for the three months ended March 31, 2023. The increase in Adjusted EBITDA was principally due to an increase in revenue.

Depreciation and Amortization

Depreciation and amortization expense was $54.1 million for the three months ended March 31, 2024, compared to $52.4 million for the three months ended March 31, 2023.

Income from Operations

For the three months ended March 31, 2024, we had income from operations of $194.0 million, compared to $151.5 million for the three months ended March 31, 2023. The increase in income from operations is principally attributable to increases in revenue within our Critical Illness Recovery Hospital and Rehabilitation Hospital segments, as discussed above under “Revenue”.

Equity in Earnings of Unconsolidated Subsidiaries

For the three months ended March 31, 2024, we had equity in earnings of unconsolidated subsidiaries of $10.4 million, compared to $8.6 million for the three months ended March 31, 2023. The increase in equity in earnings is principally due to the improved operating performance of our rehabilitation businesses in which we are a minority owner.

Interest

Our term loan is subject to an interest rate cap, which limits the variable interest rate to 1.0% on $2.0 billion of principal outstanding under the term loan. The Term SOFR rate was 5.33% at March 31, 2024, compared to the one-month LIBOR rate of 4.86% at March 31, 2023. Interest expense was $50.8 million for the three months ended March 31, 2024, compared to $48.6 million for the three months ended March 31, 2023. The increase in interest expense was principally due to the increase in the borrowing spread on the term loan resulting from Amendment No. 8 to the senior secured credit agreement.

Income Taxes

We recorded income tax expense of $36.5 million for the three months ended March 31, 2024, which represented an effective tax rate of 23.7%. We recorded income tax expense of $26.2 million for the three months ended March 31, 2023, which represented an effective tax rate of 23.5%.

30

Liquidity and Capital Resources

Cash Flows for the Three Months Ended March 31, 2024 and Three Months Ended March 31, 2023

In the following, we discuss cash flows from operating activities, investing activities, and financing activities.

	Three Months Ended March 31,
	2023		2024
	(in thousands)
Net cash provided by (used in) operating activities	$	51,440	$	(66,689)
Net cash used in investing activities	(69,062)		(57,657)
Net cash provided by financing activities	3,419		132,960
Net increase (decrease) in cash and cash equivalents	(14,203)		8,614
Cash and cash equivalents at beginning of period	97,906		84,006
Cash and cash equivalents at end of period	$	83,703	$	92,620

Operating activities used $66.7 million of cash flows for the three months ended March 31, 2024, compared to $51.4 million of cash flows provided by operating activities for the three months ended March 31, 2023. The change in cash flows provided by operating activities year over year is principally due to an increase in accounts receivable, partially offset by an increase in net income. Our patient billing and collection processes were impacted by the cyber attack on Change Healthcare, which was a driver of the increase in our accounts receivable, in addition to the increase in revenue.

Our days sales outstanding was 58 days at March 31, 2024, compared to 52 days at December 31, 2023. Our days sales outstanding was 54 days at March 31, 2023, compared to 55 days at December 31, 2022. Our days sales outstanding will fluctuate based upon variability in our collection cycles and patient volumes. The increase in our days sales outstanding at March 31, 2024 was primarily due to the impact of the Change Healthcare cybersecurity incident.

Investing activities used $57.7 million of cash flows for the three months ended March 31, 2024. The principal uses of cash were $52.5 million for purchases of property, equipment, and other assets, and $5.4 million for investments in and acquisitions of businesses. Investing activities used $69.1 million of cash flows for the three months ended March 31, 2023. The principal uses of cash were $58.9 million for purchases of property, equipment, and other assets, and $10.2 million for investments in and acquisitions of businesses.

Financing activities provided $133.0 million of cash flows for the three months ended March 31, 2024. The principal source of cash was net borrowings under our revolving facility of $230.0 million. The principal uses of cash were payments of $79.1 million on our term loan, $16.0 million of dividend payments to common stockholders, and $12.8 million for distributions to and purchases of non-controlling interests. Financing activities provided $3.4 million of cash flows for the three months ended March 31, 2023. The principal source of cash was net borrowings under our revolving facility of $15.0 million and net borrowings on our other debt of $10.3 million. The principal uses of cash were $15.9 million of dividend payments to common stockholders and $8.0 million for distributions to and purchases of non-controlling interests.

31

Capital Resources

Working capital.  We had net working capital of $256.0 million at March 31, 2024, compared to $9.2 million at December 31, 2023. The increase in net working capital was principally due to an increase in accounts receivable and a decrease in our accrued expenses.

Credit facilities. At March 31, 2024, Select had outstanding borrowings under its credit facilities consisting of a $2,013.4 million term loan (excluding unamortized original issue discounts and debt issuance costs of $14.1 million) and borrowings of $510.0 million under its revolving facility. At March 31, 2024, Select had $202.4 million of availability under its revolving facility after giving effect to $57.6 million of outstanding letters of credit.

Stock Repurchase Program.  Holdings’ Board of Directors has authorized a common stock repurchase program to repurchase up to $1.0 billion worth of shares of its common stock. The common stock repurchase program will remain in effect until December 31, 2025, unless further extended or earlier terminated by the Board of Directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate. Holdings funds this program with cash on hand and borrowings under its revolving facility. Holdings did not repurchase shares under the program during the three months ended March 31, 2024. Since the inception of the program through March 31, 2024, Holdings has repurchased 48,234,823 shares at a cost of approximately $600.3 million, or $12.45 per share, which includes transaction costs. The Inflation Reduction Act of 2022, which enacted a 1% excise tax on stock repurchases that exceed $1.0 million, became effective January 1, 2023.

Use of Capital Resources.  We may from time to time pursue opportunities to develop new joint venture relationships with large, regional health systems and other healthcare providers. We also intend to open new outpatient rehabilitation clinics and occupational health centers in local areas that we currently serve where we can benefit from existing referral relationships and brand awareness to produce incremental growth. In addition to our development activities, we may grow through opportunistic acquisitions.

Liquidity

We believe our internally generated cash flows and borrowing capacity under our revolving facility will allow us to finance our operations in both the short and long term. As of March 31, 2024, we had cash and cash equivalents of $92.6 million and $202.4 million of availability under the revolving facility after giving effect to $510.0 million of outstanding borrowings and $57.6 million of outstanding letters of credit.

We may from time to time seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity securities, in open market purchases, privately negotiated transactions, tender offers or otherwise. Such repurchases or exchanges, if any, may be funded from operating cash flows or other sources and will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

Dividend

On May 1, 2024, our Board of Directors declared a cash dividend of $0.125 per share. The dividend will be payable on or about May 30, 2024 to stockholders of record as of the close of business on May 16, 2024.

There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of our Board of Directors after taking into account various factors, including, but not limited to, our financial condition, operating results, available cash and current and anticipated cash needs, the terms of our indebtedness, and other factors our Board of Directors may deem to be relevant.

Effects of Inflation

The healthcare industry is labor intensive and our largest expenses are labor related costs. Wage and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. We have recently experienced higher labor costs related to an inflationary environment and competitive labor market. In addition, suppliers have passed along rising costs to us in the form of higher prices. We cannot predict our ability to pass along cost increases to our customers.

Recent Accounting Pronouncements

Refer to Note 2 – Accounting Policies of the notes to our condensed consolidated financial statements included herein for information regarding recent accounting pronouncements.

32

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to interest rate risk in connection with our variable rate long-term indebtedness. Our principal interest rate exposure relates to the loans outstanding under our credit facilities, which bear interest rates that are indexed against Term SOFR.

At March 31, 2024, Select had outstanding borrowings under its credit facilities consisting of a $2,013.4 million term loan (excluding unamortized original issue discounts and debt issuance costs of $14.1 million) and $510.0 million of borrowings under its revolving facility.

In order to mitigate our exposure to rising interest rates, we have an interest rate cap which limits the Term SOFR rate to 1.0% on $2.0 billion of principal outstanding under our term loan. The agreement applies to interest payments through September 30, 2024. As of March 31, 2024, the Term SOFR rate was 5.33%. As of March 31, 2024, $13.4 million of our term loan borrowings are subject to variable interest rates. Subsequent to the expiration of our interest rate cap on September 30, 2024, all of our term loan borrowings will be subject to variable interest rates.

As of March 31, 2024, each 0.25% increase in market interest rates will impact the annual interest expense on our variable rate debt by $3.8 million per year, which includes the impact of the expiration of the interest rate cap on September 30, 2024.

ITEM 4.  CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered in this report. Based on this evaluation, as of March 31, 2024, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures, including the accumulation and communication of disclosure to our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding disclosure, are effective to provide reasonable assurance that material information required to be included in our periodic SEC reports is recorded, processed, summarized, and reported within the time periods specified in the relevant SEC rules and forms.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) identified in connection with the evaluation required by Rule 13a-15(d) of the Securities Exchange Act of 1934 that occurred during the first quarter ended March 31, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there is only reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions.

33

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Refer to the “Litigation” section contained within Note 14 – Commitments and Contingencies of the notes to our condensed consolidated financial statements included herein.

ITEM 1A. RISK FACTORS

There have been no material changes from our risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases of Equity Securities by the Issuer

Holdings’ Board of Directors authorized a common stock repurchase program to repurchase up to $1.0 billion worth of shares of its common stock. The program will remain in effect until December 31, 2025, unless further extended or earlier terminated by the Board of Directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Holdings deems appropriate.

During the three months ended March 31, 2024, Holdings did not repurchase shares under the authorized common stock repurchase program. The common stock repurchase program has an available capacity of $399.7 million as of March 31, 2024.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Plans

During the three months ended March 31, 2024, none of our directors or executive officers adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.

34

ITEM 6. EXHIBITS

Number	Description
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Executive Vice President and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer, and Executive Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

35

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

SELECT MEDICAL HOLDINGS CORPORATION
By:	/s/ Michael F. Malatesta
	Michael F. Malatesta
	Executive Vice President and Chief Financial Officer
	(Duly Authorized Officer)
By:	/s/ Christopher S. Weigl
	Christopher S. Weigl
	Senior Vice President, Controller & Chief Accounting Officer
	(Principal Accounting Officer)

Dated:  May 2, 2024

36

EX-31.1

EXHIBIT 31.1

SELECT MEDICAL HOLDINGS CORPORATION

CERTIFICATIONS PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, David S. Chernow, certify that:

1.    I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 2, 2024	/s/ David S. Chernow
	David S. Chernow
	Chief Executive Officer

EX-31.2

EXHIBIT 31.2

SELECT MEDICAL HOLDINGS CORPORATION

CERTIFICATIONS PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION

I, Michael F. Malatesta, certify that:

1.    I have reviewed this quarterly report on Form 10-Q of Select Medical Holdings Corporation;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 2, 2024	/s/ Michael F. Malatesta
	Michael F. Malatesta
	Executive Vice President and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Select Medical Holdings Corporation (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, David S. Chernow and Michael F. Malatesta, Chief Executive Officer and Chief Financial Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:

(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

May 2, 2024

/s/ David S. Chernow

David S. Chernow

Chief Executive Officer

/s/ Michael F. Malatesta

Michael F. Malatesta

Executive Vice President and Chief Financial Officer

XML

Cover - shares	3 Months Ended
	Mar. 31, 2024	Apr. 30, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-34465
Entity Registrant Name	SELECT MEDICAL HOLDINGS CORP
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-1764048
Entity Address, Address Line One	4714 Gettysburg Road
Entity Address, Address Line Two	P.O. Box 2034
Entity Address, City or Town	Mechanicsburg
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	17055
City Area Code	717
Local Phone Number	972-1100
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	SEM
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		130,031,562
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001320414

XML

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 92,620	$ 84,006
Accounts receivable	1,134,788	940,335
Prepaid income taxes	9,034	22,726
Current portion of interest rate cap contract	42,660	58,962
Other current assets	161,238	151,617
Total Current Assets	1,440,340	1,257,646
Operating lease right-of-use assets	1,176,713	1,188,616
Property and equipment, net	1,024,626	1,023,561
Goodwill	3,517,071	3,513,170
Identifiable intangible assets, net	324,125	329,916
Other assets	375,388	376,722
Total Assets	7,858,263	7,689,631
Current Liabilities:
Overdrafts	28,534	30,274
Current operating lease liabilities	245,617	245,400
Current portion of long-term debt and notes payable	60,184	70,329
Accounts payable	163,551	174,312
Accrued and other liabilities	686,491	728,150
Total Current Liabilities	1,184,377	1,248,465
Non-current operating lease liabilities	1,015,160	1,025,867
Long-term debt, net of current portion	3,758,631	3,587,675
Non-current deferred tax liability	133,987	143,306
Other non-current liabilities	100,175	110,303
Total Liabilities	6,192,330	6,115,616
Commitments and contingencies (Note 14)
Redeemable non-controlling interests	28,290	26,297
Stockholders’ Equity:
Common stock, $0.001 par value, 700,000,000 shares authorized, 128,369,492 and 128,357,832 shares issued and outstanding at 2023 and 2024, respectively	128	128
Capital in excess of par	505,403	493,413
Retained earnings	830,821	751,856
Accumulated other comprehensive income	30,930	42,907
Total Stockholders’ Equity	1,367,282	1,288,304
Non-controlling interests	270,361	259,414
Total Equity	1,637,643	1,547,718
Total Liabilities and Equity	$ 7,858,263	$ 7,689,631

XML

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	700,000,000	700,000,000
Common stock, shares issued (in shares)	128,357,832	128,369,492
Common stock, shares outstanding (in shares)	128,357,832	128,369,492

XML

Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 1,788,809	$ 1,664,980
Costs and expenses:
Cost of services, exclusive of depreciation and amortization	1,494,610	1,418,819
General and administrative	48,447	42,279
Depreciation and amortization	54,069	52,425
Total costs and expenses	1,597,126	1,513,523
Other operating income	2,284	0
Income from operations	193,967	151,457
Other income and expense:
Equity in earnings of unconsolidated subsidiaries	10,421	8,556
Interest expense	(50,763)	(48,571)
Income before income taxes	153,625	111,442
Income tax expense	36,458	26,185
Net income	117,167	85,257
Less: Net income attributable to non-controlling interests	20,270	14,452
Net income attributable to Select Medical Holdings Corporation	$ 96,897	$ 70,805
Earnings per common share (Note 13):
Basic (in dollars per share)	$ 0.75	$ 0.56
Diluted (in dollars per share)	$ 0.75	$ 0.56

XML

Condensed Consolidated Statements of Comprehensive Income (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 117,167	$ 85,257
Other comprehensive loss, net of tax:
Gain (loss) on interest rate cap contract	4,370	(2,696)
Reclassification adjustment for gains included in net income	(16,347)	(13,252)
Net change, net of tax benefit of $5,175, and $3,782	(11,977)	(15,948)
Comprehensive income	105,190	69,309
Less: Comprehensive income attributable to non-controlling interests	20,270	14,452
Comprehensive income attributable to Select Medical Holdings Corporation	$ 84,920	$ 54,857

XML

Condensed Consolidated Statements of Comprehensive Income (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Tax benefit (expense) on components of other comprehensive income	$ 3,782	$ 5,175

XML

Condensed Consolidated Statements of Changes in Equity and Income (unaudited) - USD ($) $ in Thousands	Total	Total Stockholders’ Equity	Common Stock	Capital in Excess of Par	Retained Earnings	Accumulated Other Comprehensive Income	Non-controlling Interests
Beginning balance (in shares) at Dec. 31, 2022			127,173,000
Beginning balance at Dec. 31, 2022	$ 1,356,564	$ 1,121,922	$ 127	$ 452,183	$ 581,010	$ 88,602	$ 234,642
Increase (Decrease) in Stockholders' Equity
Net income attributable to Select Medical Holdings Corporation	70,805	70,805			70,805
Net income attributable to non-controlling interests	12,811	0					12,811
Cash dividends declared for common stockholders ($0.125 per share)	(15,897)	(15,897)			(15,897)
Issuance of restricted stock (in shares)			3,000
Issuance of restricted stock	0	0	$ 0	0
Vesting of restricted stock	10,003	10,003		10,003
Issuance of non-controlling interests	2,731	0					2,731
Non-controlling interests acquired in business combination	3,877	0					3,877
Distributions to and purchases of non-controlling interests	(6,069)	0					(6,069)
Redemption value adjustment on non-controlling interests	(436)	(436)			(436)
Other comprehensive loss	(15,948)	(15,948)				(15,948)
Other	0	0		(1)	1
Ending balance (in shares) at Mar. 31, 2023			127,176,000
Ending balance at Mar. 31, 2023	$ 1,418,441	1,170,449	$ 127	462,185	635,483	72,654	247,992
Beginning balance (in shares) at Dec. 31, 2023	128,369,492		128,369,000
Beginning balance at Dec. 31, 2023	$ 1,547,718	1,288,304	$ 128	493,413	751,856	42,907	259,414
Increase (Decrease) in Stockholders' Equity
Net income attributable to Select Medical Holdings Corporation	96,897	96,897			96,897
Net income attributable to non-controlling interests	17,845	0					17,845
Cash dividends declared for common stockholders ($0.125 per share)	(16,045)	(16,045)			(16,045)
Issuance of restricted stock (in shares)			1,000
Issuance of restricted stock	0	0	$ 0	0
Forfeitures of unvested restricted stock (in shares)			(12,000)
Forfeitures of unvested restricted stock	14	14	$ 0	0	14
Vesting of restricted stock	11,596	11,596		11,596
Issuance of non-controlling interests	4,002	0					4,002
Distributions to and purchases of non-controlling interests	(10,506)	394		394			(10,900)
Redemption value adjustment on non-controlling interests	(1,901)	(1,901)			(1,901)
Other comprehensive loss	$ (11,977)	(11,977)				(11,977)
Ending balance (in shares) at Mar. 31, 2024	128,357,832		128,358,000
Ending balance at Mar. 31, 2024	$ 1,637,643	$ 1,367,282	$ 128	$ 505,403	$ 830,821	$ 30,930	$ 270,361

XML

Condensed Consolidated Statements of Changes in Equity and Income (unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Stockholders' Equity [Abstract]
Cash dividend declared (in dollars per share)	$ 0.125	$ 0.125

XML

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating activities
Net income	$ 117,167	$ 85,257
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	12,374	2,566
Depreciation and amortization	54,069	52,425
Provision for expected credit losses	854	429
Equity in earnings of unconsolidated subsidiaries	(10,421)	(8,556)
(Gain) loss on sale or disposal of assets	44	(7)
Stock compensation expense	11,610	10,181
Amortization of debt discount, premium, and issuance costs	750	565
Deferred income taxes	(6,891)	(2,601)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(195,308)	(55,397)
Other current assets	(9,611)	(11,742)
Other assets	2,363	3,659
Accounts payable	(5,718)	(4,564)
Accrued expenses	(37,971)	(20,775)
Net cash provided by (used in) operating activities	(66,689)	51,440
Investing activities
Business combinations, net of cash acquired	(5,405)	(397)
Purchases of property, equipment, and other assets	(52,517)	(58,885)
Investment in businesses	0	(9,800)
Proceeds from sale of assets and businesses	265	20
Net cash used in investing activities	(57,657)	(69,062)
Financing activities
Borrowings on revolving facilities	495,000	225,000
Payments on revolving facilities	(265,000)	(210,000)
Payments on term loans	(79,085)	0
Borrowings of other debt	17,728	21,448
Principal payments on other debt	(9,061)	(11,170)
Dividends paid to common stockholders	(16,045)	(15,897)
Decrease in overdrafts	(1,740)	(724)
Proceeds from issuance of non-controlling interests	4,002	2,731
Distributions to and purchases of non-controlling interests	(12,839)	(7,969)
Net cash provided by financing activities	132,960	3,419
Net increase (decrease) in cash and cash equivalents	8,614	(14,203)
Cash and cash equivalents at beginning of period	84,006	97,906
Cash and cash equivalents at end of period	92,620	83,703
Supplemental information
Cash paid for interest, excluding amounts received of $17,828 and $22,515 under the interest rate cap contract	88,834	84,531
Cash paid for taxes	$ 604	$ 336

XML

Condensed Consolidated Statements of Cash Flows (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Cash Flows [Abstract]
Interest received under interest rate cash flow hedge	$ 22,515	$ 17,828

XML

Basis of Presentation

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Basis of Presentation

The unaudited condensed consolidated financial statements of Select Medical Holdings Corporation (“Holdings”) include the accounts of its wholly owned subsidiary, Select Medical Corporation (“Select”). Holdings conducts substantially all of its business through Select and its subsidiaries. Holdings, Select, and Select’s subsidiaries are collectively referred to as the “Company.” The unaudited condensed consolidated financial statements of the Company as of March 31, 2024, and for the three month periods ended March 31, 2023 and 2024, have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting and the accounting principles generally accepted in the United States of America (“GAAP”). Accordingly, certain information and disclosures required by GAAP, which are normally included in the notes to the consolidated financial statements, have been condensed or omitted pursuant to those rules and regulations, although the Company believes the disclosure is adequate to make the information presented not misleading. In the opinion of management, such information contains all adjustments, which are normal and recurring in nature, necessary for a fair statement of the financial position, results of operations and cash flow for such periods. All significant intercompany transactions and balances have been eliminated.

The results of operations for the three months ended March 31, 2024, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2024. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023, contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 22, 2024.

XML

Accounting Policies

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Accounting Policies

Accounting Policies

Recent Accounting Guidance Not Yet Adopted

Segment Reporting

In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve disclosure of segment information so that investors can better understand an entity’s overall performance. The ASU requires entities to quantitatively disclose significant segment expenses that are regularly provided to the chief operating decision maker for each reportable segment, as well as the amount of other segment items for each reportable segment and a description of what the other segment items are comprised. Disclosure of multiple measures of profit or loss will be permitted by the ASU.

The ASU is effective for annual reporting periods beginning on or after December 15, 2023, and interim periods with fiscal years beginning after December 15, 2024; however, early adoption is permitted. The ASU is required to be applied retrospectively to all periods presented in the financial statements. The Company is currently reviewing the impact that ASU 2023-07 will have on the disclosures in our consolidated financial statements.

Income Taxes

In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve the transparency and decision usefulness of income tax disclosures. The ASU includes enhanced requirements on the rate reconciliation, including specific categories that must be disclosed, and provides a threshold over which reconciling items must be disclosed. The amendments in the update also require annual disclosure of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as any individual jurisdictions in which income taxes paid is greater than 5% of total income taxes paid.

The ASU is effective for annual periods beginning after December 15, 2024; however early adoption is permitted. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2023-09 will have to the disclosures in our consolidated financial statements.

Recently Adopted Accounting Guidance

Leases

In March 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-01, Leases (Topic 842): Common Control Arrangements, which requires companies to amortize leasehold improvements associated with related party leases under common control over the useful life of the leasehold improvement to the common control group. The ASU is effective for annual reporting periods beginning on or after December 15, 2023; however, early adoption is permitted. The ASU can either be applied prospectively or retrospectively.

The Company adopted this ASU using the prospective method of transition on January 1, 2024. There was not a material impact on the Company’s consolidated financial statements upon adoption.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.

XML

Credit Risk Concentrations

3 Months Ended

Mar. 31, 2024

Credit Loss [Abstract]

Credit Risk Concentrations

Credit Risk Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash balances and accounts receivable. The Company’s excess cash is held with large financial institutions. The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements.

Because of the diversity in the Company’s non-governmental third-party payor base, as well as their geographic dispersion, accounts receivable due from the Medicare program represent the Company’s only significant concentration of credit risk. Approximately 17% and 20% of the Company’s accounts receivable is due from Medicare at both December 31, 2023, and March 31, 2024, respectively.

XML

Redeemable Non-Controlling Interests

3 Months Ended

Mar. 31, 2024

Noncontrolling Interest [Abstract]

Redeemable Non-Controlling Interests

Redeemable Non-Controlling Interests

The ownership interests held by outside parties in subsidiaries, which include limited liability companies and limited partnerships, controlled by the Company are classified as non-controlling interests. Some of the Company’s non-controlling ownership interests consist of outside parties that have certain redemption rights that, if exercised, require the Company to purchase the parties’ ownership interests. These interests are classified and reported as redeemable non-controlling interests and have been adjusted to their redemption values, after the attribution of net income or loss.

The changes in redeemable non-controlling interests are as follows:

	Three Months Ended March 31,
	2023		2024
	(in thousands)
Balance as of January 1	$	34,043	$	26,297
Net income attributable to redeemable non-controlling interests	1,641		2,425
Distributions to redeemable non-controlling interests	(1,900)		(2,333)
Redemption value adjustment on redeemable non-controlling interests	436		1,901
Other	179		—
Balance as of March 31	$	34,399	$	28,290

XML

Variable Interest Entities

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Variable Interest Entities

Variable Interest Entities

Certain states prohibit the “corporate practice of medicine,” which restricts the Company from owning medical practices which directly employ physicians or therapists and from exercising control over medical decisions by physicians and therapists. In these states, the Company enters into long-term management agreements with medical practices that are owned by licensed physicians or therapists, which, in turn, employ or contract with physicians or therapists who provide professional medical services. The management agreements provide for the Company to direct the transfer of ownership of the medical practices. Based on the provisions of the management agreements, the medical practices are variable interest entities for which the Company is the primary beneficiary.

As of December 31, 2023, and March 31, 2024, the total assets of the Company’s variable interest entities were $246.4 million and $263.7 million, respectively, and are principally comprised of accounts receivable. As of December 31, 2023, and March 31, 2024, the total liabilities of the Company’s variable interest entities were $84.3 million and $85.4 million, respectively, and are principally comprised of accounts payable and accrued expenses. These variable interest entities have obligations payable for services received under their management agreements with the Company of $161.8 million and $179.5 million as of December 31, 2023, and March 31, 2024, respectively. These intercompany balances are eliminated in consolidation.

XML

Leases

3 Months Ended

Mar. 31, 2024

Leases [Abstract]

Leases

Leases

The Company’s total lease cost is as follows:

	Three Months Ended March 31, 2023						Three Months Ended March 31, 2024
	Unrelated Parties		Related Parties		Total		Unrelated Parties		Related Parties		Total
	(in thousands)
Operating lease cost	$	76,632	$	1,834	$	78,466	$	79,055	$	1,834	$	80,889
Finance lease cost:
Amortization of right-of-use assets	394		—		394		354		—		354
Interest on lease liabilities	320		—		320		304		—		304
Variable lease cost	15,761		84		15,845		17,076		—		17,076
Sublease income	(1,678)		—		(1,678)		(1,760)		—		(1,760)
Total lease cost	$	91,429	$	1,918	$	93,347	$	95,029	$	1,834	$	96,863

Leases

Leases

The Company’s total lease cost is as follows:

	Three Months Ended March 31, 2023						Three Months Ended March 31, 2024
	Unrelated Parties		Related Parties		Total		Unrelated Parties		Related Parties		Total
	(in thousands)
Operating lease cost	$	76,632	$	1,834	$	78,466	$	79,055	$	1,834	$	80,889
Finance lease cost:
Amortization of right-of-use assets	394		—		394		354		—		354
Interest on lease liabilities	320		—		320		304		—		304
Variable lease cost	15,761		84		15,845		17,076		—		17,076
Sublease income	(1,678)		—		(1,678)		(1,760)		—		(1,760)
Total lease cost	$	91,429	$	1,918	$	93,347	$	95,029	$	1,834	$	96,863

XML

Long-Term Debt and Notes Payable

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Long-Term Debt and Notes Payable

Long-Term Debt and Notes Payable

As of March 31, 2024, the Company’s long-term debt and notes payable are as follows:

	Principal Outstanding		Unamortized Premium (Discount)		Unamortized Issuance Costs		Carrying Value		Fair Value
	(in thousands)
6.250% senior notes	$	1,225,000	$	14,041	$	(7,186)	$	1,231,855	$	1,226,531
Credit facilities:
Revolving facility	510,000		—		—		510,000		506,175
Term loan	2,013,400		(11,088)		(2,973)		1,999,339		2,015,917
Other debt, including finance leases	77,667		—		(46)		77,621		77,621
Total debt	$	3,826,067	$	2,953	$	(10,205)	$	3,818,815	$	3,826,244

Principal maturities of the Company’s long-term debt and notes payable are approximately as follows:

	2024		2025		2026		2027		2028		Thereafter		Total
	(in thousands)
6.250% senior notes	$	—	$	—	$	1,225,000	$	—	$	—	$	—	$	1,225,000
Credit facilities:
Revolving facility	—		—		—		510,000		—		—		510,000
Term loan	—		—		—		2,013,400		—		—		2,013,400
Other debt, including finance leases	58,155		3,151		2,461		1,941		1,620		10,339		77,667
Total debt	$	58,155	$	3,151	$	1,227,461	$	2,525,341	$	1,620	$	10,339	$	3,826,067

As of December 31, 2023, the Company’s long-term debt and notes payable are as follows:

	Principal Outstanding		Unamortized Premium (Discount)		Unamortized Issuance Costs		Carrying Value		Fair Value
	(in thousands)
6.250% senior notes	$	1,225,000	$	15,533	$	(7,937)	$	1,232,596	$	1,228,063
Credit facilities:
Revolving facility	280,000		—		—		280,000		278,600
Term loan	2,092,485		(12,040)		(3,229)		2,077,216		2,092,485
Other debt, including finance leases	68,255		—		(63)		68,192		68,192
Total debt	$	3,665,740	$	3,493	$	(11,229)	$	3,658,004	$	3,667,340

XML

Accrued and other liabilities

3 Months Ended

Mar. 31, 2024

Payables and Accruals [Abstract]

Accrued and other liabilities

Accrued and other liabilities

The following table sets forth the components of accrued and other liabilities on the Condensed Consolidated Balance Sheets:

	December 31, 2023		March 31, 2024
Accrued payroll	$	238,768	$	184,801
Accrued vacation	157,748		164,113
Accrued interest	32,472		14,438
Accrued other	297,663		292,587
Income taxes payable	1,499		30,552
Accrued and other liabilities	$	728,150	$	686,491

XML

Interest Rate Cap

3 Months Ended

Mar. 31, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Interest Rate Cap

Interest Rate Cap

The Company is subject to market risk exposure arising from changes in interest rates on its term loan, which bears interest at a rate which is indexed to one-month Term SOFR. The Company’s objective in using an interest rate derivative is to mitigate its exposure to increases in interest rates. The interest rate cap limits the Company’s exposure to increases in the variable rate index to 1.0% on $2.0 billion of principal outstanding under the term loan, as the interest rate cap provides for payments from the counterparty when interest rates rise above 1.0%. The interest rate cap has a $2.0 billion notional amount and is effective through September 30, 2024. The Company will pay a monthly premium for the interest rate cap over the term of the agreement. The annual premium is equal to 0.0916% of the notional amount, or approximately $1.8 million.

The interest rate cap has been designated as a cash flow hedge and is highly effective at offsetting the changes in cash outflows when the variable rate index exceeds 1.0%. Changes in the fair value of the interest rate cap, net of tax, are recognized in other comprehensive income and are reclassified out of accumulated other comprehensive income and into interest expense when the hedged interest obligations affect earnings.

The following table outlines the changes in accumulated other comprehensive income (loss), net of tax, during the periods presented:

	Three Months Ended March 31,
	2023		2024
	(in thousands)
Balance as of January 1	$	88,602	$	42,907
Gain (loss) on interest rate cap cash flow hedge	(2,696)		4,370
Amounts reclassified from accumulated other comprehensive income	(13,252)		(16,347)
Balance as of March 31	$	72,654	$	30,930

The effects on net income of amounts reclassified from accumulated other comprehensive income are as follows:

		Three Months Ended March 31,
Statement of Operations		2023		2024
	(in thousands)
Gains included in interest expense		$	17,552	$	21,509
Income tax expense		(4,300)		(5,162)
Amounts reclassified from accumulated other comprehensive income		$	13,252	$	16,347

The Company expects that approximately $40.7 million of estimated pre-tax gains will be reclassified from accumulated other comprehensive income into interest expense through the expiration of the interest rate cap on September 30, 2024.

Refer to Note 10 – Fair Value of Financial Instruments for information on the fair value of the Company’s interest rate cap contract and its balance sheet classification.

XML

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Financial instruments which are measured at fair value, or for which a fair value is disclosed, are classified in the fair value hierarchy, as outlined below, on the basis of the observability of the inputs used in the fair value measurement:

•Level 1 – inputs are based upon quoted prices for identical instruments in active markets.

•Level 2 – inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data.

•Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the instrument.

The Company’s interest rate cap contract is recorded at its fair value in the condensed consolidated balance sheets on a recurring basis. The fair value of the interest rate cap contract is based upon a model-derived valuation using observable market inputs, such as interest rates and interest rate volatility, and the strike price.

Financial Instrument	Balance Sheet Classification	Level	December 31, 2023		March 31, 2024
Asset:			(in thousands)
Interest rate cap contract, current portion	Current portion of interest rate cap contract	Level 2	$	58,962	$	42,660

The Company does not measure its indebtedness at fair value in its condensed consolidated balance sheets. The fair value of the credit facilities is based on quoted market prices for this debt in the syndicated loan market. The fair value of the senior notes is based on quoted market prices. The carrying value of the Company’s other debt, as disclosed in Note 7 – Long-Term Debt and Notes Payable, approximates fair value.

		December 31, 2023				March 31, 2024
Financial Instrument	Level	Carrying Value		Fair Value		Carrying Value		Fair Value
		(in thousands)
6.250% senior notes	Level 2	$	1,232,596	$	1,228,063	$	1,231,855	$	1,226,531
Credit facilities:
Revolving facility	Level 2	280,000		278,600		510,000		506,175
Term loan	Level 2	2,077,216		2,092,485		1,999,339		2,015,917

The Company’s other financial instruments, which primarily consist of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value because of the short-term maturities of these instruments.

XML

Segment Information

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Segment Information

Segment Information

The Company’s reportable segments consist of the critical illness recovery hospital segment, rehabilitation hospital segment, outpatient rehabilitation segment, and Concentra segment. Other activities include the Company’s corporate shared services, certain investments, and employee leasing services with non-consolidating subsidiaries.

The Company evaluates the performance of its segments based on Adjusted EBITDA. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, transaction costs associated with the Concentra separation, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries. The Company has provided additional information regarding its reportable segments, such as total assets, which contributes to the understanding of the Company and provides useful information to the users of the consolidated financial statements.

The following tables summarize selected financial data for the Company’s reportable segments.

	Three Months Ended March 31,
	2023		2024
	(in thousands)
Revenue:
Critical illness recovery hospital	$	593,926	$	655,880
Rehabilitation hospital	231,462		265,700
Outpatient rehabilitation	295,903		303,158
Concentra	456,298		467,598
Other	87,391		96,473
Total Company	$	1,664,980	$	1,788,809
Adjusted EBITDA:
Critical illness recovery hospital	$	76,773	$	115,940
Rehabilitation hospital	47,216		61,400
Outpatient rehabilitation	30,199		24,928
Concentra	93,748		96,142
Other	(33,873)		(36,493)
Total Company	$	214,063	$	261,917
Total assets:
Critical illness recovery hospital	$	2,507,265	$	2,608,979
Rehabilitation hospital	1,203,069		1,233,828
Outpatient rehabilitation	1,397,823		1,423,740
Concentra	2,300,632		2,362,848
Other	290,947		228,868
Total Company	$	7,699,736	$	7,858,263
Purchases of property, equipment, and other assets:
Critical illness recovery hospital	$	23,658	$	15,941
Rehabilitation hospital	8,582		7,101
Outpatient rehabilitation	9,932		9,500
Concentra	14,400		17,231
Other	2,313		2,744
Total Company	$	58,885	$	52,517

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Adjusted EBITDA	$	76,773	$	47,216	$	30,199	$	93,748	$	(33,873)
Depreciation and amortization	(16,637)		(6,888)		(8,457)		(18,310)		(2,133)
Stock compensation expense	—		—		—		(178)		(10,003)
Income (loss) from operations	$	60,136	$	40,328	$	21,742	$	75,260	$	(46,009)	$	151,457
Equity in earnings of unconsolidated subsidiaries											8,556
Interest expense											(48,571)
Income before income taxes											$	111,442

	Three Months Ended March 31, 2024
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Adjusted EBITDA	$	115,940	$	61,400	$	24,928	$	96,142	$	(36,493)
Depreciation and amortization	(17,157)		(7,135)		(9,181)		(18,485)		(2,111)
Stock compensation expense	—		—		—		(166)		(11,444)
Concentra separation transaction costs(1)	—		—		—		(1,993)		(278)
Income (loss) from operations	$	98,783	$	54,265	$	15,747	$	75,498	$	(50,326)	$	193,967
Equity in earnings of unconsolidated subsidiaries											10,421
Interest expense											(50,763)
Income before income taxes											$	153,625

_______________________________________________________________________________

(1)    Concentra separation transaction costs represent incremental consulting, legal, and audit-related fees incurred in connection with the Company’s planned separation of the Concentra segment into a new, publicly traded company and are included within general and administrative expenses on the Condensed Consolidated Statements of Operations.

XML

Revenue from Contracts with Customers

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

Revenue from Contracts with Customers

The following tables disaggregate the Company’s revenue for the three months ended March 31, 2023 and 2024:

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Patient service revenue:
Medicare	$	229,383	$	110,055	$	45,801	$	243	$	—	$	385,482
Non-Medicare	363,305		109,925		231,985		454,598		—		1,159,813
Total patient services revenues	592,688		219,980		277,786		454,841		—		1,545,295
Other revenue	1,238		11,482		18,117		1,457		87,391		119,685
Total revenue	$	593,926	$	231,462	$	295,903	$	456,298	$	87,391	$	1,664,980

	Three Months Ended March 31, 2024
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Patient service revenue:
Medicare	$	226,261	$	126,386	$	45,841	$	266	$	—	$	398,754
Non-Medicare	428,666		126,577		239,613		465,601		—		1,260,457
Total patient services revenues	654,927		252,963		285,454		465,867		—		1,659,211
Other revenue	953		12,737		17,704		1,731		96,473		129,598
Total revenue	$	655,880	$	265,700	$	303,158	$	467,598	$	96,473	$	1,788,809

XML

Earnings per Share

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Earnings per Share

Earnings per Share

The Company’s capital structure includes common stock and unvested restricted stock awards. To compute earnings per share (“EPS”), the Company applies the two-class method because the Company’s unvested restricted stock awards are participating securities which are entitled to participate equally with the Company’s common stock in undistributed earnings. Application of the Company’s two-class method is as follows:

(i)Net income attributable to the Company is reduced by the amount of dividends declared and by the contractual amount of dividends that must be paid for the current period for each class of stock. There were no contractual dividends paid for the three months ended March 31, 2023 and 2024.

(ii)The remaining undistributed net income of the Company is then equally allocated to its common stock and unvested restricted stock awards, as if all of the earnings for the period had been distributed. The total net income allocated to each security is determined by adding both distributed and undistributed net income for the period.

(iii)The net income allocated to each security is then divided by the weighted average number of outstanding shares for the period to determine the EPS for each security considered in the two-class method.

The following table sets forth the net income attributable to the Company, its common shares outstanding, and its participating securities outstanding.

	Basic and Diluted EPS
		Three Months Ended March 31,
		2023		2024
	(in thousands)
Net income		$	85,257	$	117,167
Less: net income attributable to non-controlling interests		14,452		20,270
Net income attributable to the Company		70,805		96,897
Less: Distributed and undistributed income attributable to participating securities		2,573		3,398
Distributed and undistributed income attributable to common shares		$	68,232	$	93,499

The following tables set forth the computation of EPS under the two-class method:

	Three Months Ended March 31,
	2023					2024
	Net Income Allocation		Shares(1)	Basic and Diluted EPS		Net Income Allocation		Shares(1)	Basic and Diluted EPS
	(in thousands, except for per share amounts)
Common shares	$	68,232	122,553	$	0.56	$	93,499	123,859	$	0.75
Participating securities	2,573		4,622	$	0.56	3,398		4,501	$	0.75
Total Company	$	70,805				$	96,897

_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

(1)    Represents the weighted average share count outstanding during the period.

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Litigation

The Company is a party to various legal actions, proceedings, and claims (some of which are not insured), and regulatory and other governmental audits and investigations in the ordinary course of its business. The Company cannot predict the ultimate outcome of pending litigation, proceedings, and regulatory and other governmental audits and investigations. These matters could potentially subject the Company to sanctions, damages, recoupments, fines, and other penalties. The Department of Justice, Centers for Medicare & Medicaid Services (“CMS”), or other federal and state enforcement and regulatory agencies may conduct additional investigations related to the Company’s businesses in the future that may, either individually or in the aggregate, have a material adverse effect on the Company’s business, financial position, results of operations, and liquidity.

To address claims arising out of the Company’s operations, the Company maintains professional malpractice liability insurance and general liability insurance coverages through a number of different programs that are dependent upon such factors as the state where the Company is operating and whether the operations are wholly owned or are operated through a joint venture. For the Company’s wholly owned hospital and outpatient clinic operations, the Company currently maintains insurance coverages under a combination of policies with a total annual aggregate limit of up to $37.0 million for professional malpractice liability insurance and $40.0 million for general liability insurance. For the Company’s Concentra center operations, the Company currently maintains insurance coverages under a combination of policies with a total annual aggregate limit of up to $29.0 million for professional malpractice liability insurance and $29.0 million for general liability insurance. The Company’s insurance for the professional liability coverage is written on a “claims-made” basis, and its commercial general liability coverage is maintained on an “occurrence” basis. These coverages apply after a self-insured retention limit is exceeded. For the Company’s joint venture operations, the Company has designed a separate insurance program that responds to the risks of specific joint ventures. Most of the Company’s joint ventures are insured under a master program with an annual aggregate limit of up to $80.0 million, subject to a sublimit aggregate ranging from $23.0 million to $33.0 million. The policies are generally written on a “claims-made” basis. Each of these programs has either a deductible or self-insured retention limit. The Company also maintains additional types of liability insurance covering claims which, due to their nature or amount, are not covered by or not fully covered by the applicable professional malpractice and general liability insurance policies, including workers compensation, property and casualty, directors and officers, cyber liability insurance, and employment practices liability insurance coverages. Our insurance policies generally are silent with respect to punitive damages so coverage is available to the extent insurable under the law of any applicable jurisdiction, and are subject to various deductibles and policy limits. The Company reviews its insurance program annually and may make adjustments to the amount of insurance coverage and self-insured retentions in future years. Significant legal actions, as well as the cost and possible lack of available insurance, could subject the Company to substantial uninsured liabilities.

Healthcare providers are subject to lawsuits under the qui tam provisions of the federal False Claims Act. Qui tam lawsuits typically remain under seal (hence, usually unknown to the defendant) for some time while the government decides whether or not to intervene on behalf of a private qui tam plaintiff (known as a relator) and take the lead in the litigation. These lawsuits can involve significant monetary damages and penalties and award bounties to private plaintiffs who successfully bring the suits. The Company is and has been a defendant in these cases in the past, and may be named as a defendant in similar cases from time to time in the future.

Oklahoma City Investigation. On August 24, 2020, the Company and Select Specialty Hospital – Oklahoma City, Inc. (“SSH–Oklahoma City”) received civil investigative demands (“CIDs”) from the U.S. Attorney’s Office for the Western District of Oklahoma seeking responses to interrogatories and the production of various documents principally relating to the documentation, billing and reviews of medical services furnished to patients at SSH-Oklahoma City. The Company understands that the investigation arose from a qui tam lawsuit alleging billing fraud related to charges for respiratory therapy services at SSH–Oklahoma City and Select Specialty Hospital – Wichita, Inc. The Company has produced documents in response to the CIDs and is fully cooperating with this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

Physical Therapy Billing. On October 7, 2021, the Company received a letter from a Trial Attorney at the U.S. Department of Justice, Civil Division, Commercial Litigation Branch, Fraud Section (“DOJ”) stating that the DOJ, in conjunction with the U.S. Department of Health and Human Services (“HHS”), is investigating the Company in connection with potential violations of the False Claims Act, 31 U.S.C. § 3729, et seq. The letter specified that the investigation relates to the Company’s billing for physical therapy services, and indicated that the DOJ would be requesting certain records from the Company. In October and December 2021, the DOJ requested, and the Company furnished, records relating to six of the Company’s outpatient therapy clinics in Florida. In 2022 and 2023, the DOJ requested certain data relating to all of the Company’s outpatient therapy clinics nationwide, and sought information about the Company’s ability to produce additional data relating to the physical therapy services furnished by the Company’s outpatient therapy clinics and Concentra. The Company has produced data and other documents requested by the DOJ and is fully cooperating on this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

California Department of Insurance Investigation. On February 5, 2024, Concentra received a subpoena from the California Department of Insurance relating to an investigation under the California Insurance Frauds Prevention Act (“IFPA”), Cal. Ins. Code § 1871.7 et seq., which allows a whistleblower to file a false claims lawsuit based on the submission of false or fraudulent claims to insurance companies. The subpoena seeks documentation relating mainly to Concentra’s billing and coding for physical therapy claims submitted to commercial insurers and workers compensation carriers located or doing business in California. The Company has produced data and other documents requested by the California Department of Insurance and is fully cooperating on this investigation. At this time, the Company is unable to predict the timing and outcome of this matter.

Perry Johnson & Associates, Inc. Data Breach. On November 10, 2023, Perry Johnson & Associates, Inc., a third-party vendor of health information technology solutions that provides medical transcription services (“PJ&A”), notified Concentra Health Services, Inc. (“Concentra”) that certain information related to particular Concentra patients was potentially affected by a cybersecurity event. In February 2024, Concentra sent notices to almost four million patients who may have been impacted by the data breach. During the first quarter of 2024, Concentra became aware of six putative class action lawsuits files against PJ&A and Concentra related to the data breach. The first was filed in the U.S. District Court for the Eastern District of Michigan on February 19, 2024 by Elliot Curry, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that he became the victim of identity theft as a result of the PJ&A data breach and that Concentra had lax data security policies. The second was filed in the U.S. District Court for the Eastern District of New York on February 21, 2024 by Tiffany Williams and Jo Joaquim, individually and on behalf of all others similarly situated. Plaintiffs alleged, among other things, that they face an immediate and heightened risk of identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard their private information. The third was filed in the U.S. District Court for the Eastern District of Missouri on February 26, 2024 by Stephen Tate, a.k.a. Steven Tate, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that he faces a heightened and imminent risk of identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard his private information. The fourth was filed in the U.S. District Court for the Eastern District of Michigan on February 26, 2024 by Eric Franczak, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that he faces a substantially increased risk of fraud and identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard his private information. The fifth was filed in the U.S. District Court for the Eastern District of Michigan on March 6, 2024 by Lazema Johnson, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that she faces a substantially increased risk of fraud and identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard her private information. The sixth was filed in the Superior Court of California, County of Los Angeles, on April 8, 2024 by Robert Valencia, individually and on behalf of all others similarly situated. Plaintiff alleged, among other things, that he faces a substantially increased risk of fraud and identity theft as a result of the data breach and that the defendants failed to take measures to properly safeguard his private information. The Company is working with its cybersecurity risk insurance policy carrier and does not believe that the data breach or the lawsuits will have a material impact on its operations or financial performance. However, at this time, the Company is unable to predict the timing and outcome of these matters.

XML

Subsequent Events

3 Months Ended

Mar. 31, 2024

Subsequent Events [Abstract]

Subsequent Events

Subsequent Events

On May 1, 2024, the Company’s Board of Directors declared a cash dividend of $0.125 per share. The dividend will be payable on or about May 30, 2024, to stockholders of record as of the close of business on May 16, 2024.

XML

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net income attributable to Select Medical Holdings Corporation	$ 96,897	$ 70,805

XML

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML

Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Recent Accounting Guidance Not Yet Adopted and Recently Adopted Accounting Guidance

Recent Accounting Guidance Not Yet Adopted

Segment Reporting

In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve disclosure of segment information so that investors can better understand an entity’s overall performance. The ASU requires entities to quantitatively disclose significant segment expenses that are regularly provided to the chief operating decision maker for each reportable segment, as well as the amount of other segment items for each reportable segment and a description of what the other segment items are comprised. Disclosure of multiple measures of profit or loss will be permitted by the ASU.

The ASU is effective for annual reporting periods beginning on or after December 15, 2023, and interim periods with fiscal years beginning after December 15, 2024; however, early adoption is permitted. The ASU is required to be applied retrospectively to all periods presented in the financial statements. The Company is currently reviewing the impact that ASU 2023-07 will have on the disclosures in our consolidated financial statements.

Income Taxes

In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve the transparency and decision usefulness of income tax disclosures. The ASU includes enhanced requirements on the rate reconciliation, including specific categories that must be disclosed, and provides a threshold over which reconciling items must be disclosed. The amendments in the update also require annual disclosure of income taxes paid, disaggregated by federal, state, and foreign taxes, as well as any individual jurisdictions in which income taxes paid is greater than 5% of total income taxes paid.

The ASU is effective for annual periods beginning after December 15, 2024; however early adoption is permitted. The ASU can be applied either prospectively or retrospectively. The Company is currently reviewing the impact that ASU 2023-09 will have to the disclosures in our consolidated financial statements.

Recently Adopted Accounting Guidance

Leases

In March 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-01, Leases (Topic 842): Common Control Arrangements, which requires companies to amortize leasehold improvements associated with related party leases under common control over the useful life of the leasehold improvement to the common control group. The ASU is effective for annual reporting periods beginning on or after December 15, 2023; however, early adoption is permitted. The ASU can either be applied prospectively or retrospectively.

The Company adopted this ASU using the prospective method of transition on January 1, 2024. There was not a material impact on the Company’s consolidated financial statements upon adoption.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Actual results could differ from those estimates.

Credit Risk Concentrations

Credit Risk Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash balances and accounts receivable. The Company’s excess cash is held with large financial institutions. The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements.

Because of the diversity in the Company’s non-governmental third-party payor base, as well as their geographic dispersion, accounts receivable due from the Medicare program represent the Company’s only significant concentration of credit risk.

Redeemable Non-Controlling Interests

Redeemable Non-Controlling Interests

The ownership interests held by outside parties in subsidiaries, which include limited liability companies and limited partnerships, controlled by the Company are classified as non-controlling interests. Some of the Company’s non-controlling ownership interests consist of outside parties that have certain redemption rights that, if exercised, require the Company to purchase the parties’ ownership interests. These interests are classified and reported as redeemable non-controlling interests and have been adjusted to their redemption values, after the attribution of net income or loss.

Variable Interest Entities

Variable Interest Entities

Certain states prohibit the “corporate practice of medicine,” which restricts the Company from owning medical practices which directly employ physicians or therapists and from exercising control over medical decisions by physicians and therapists. In these states, the Company enters into long-term management agreements with medical practices that are owned by licensed physicians or therapists, which, in turn, employ or contract with physicians or therapists who provide professional medical services. The management agreements provide for the Company to direct the transfer of ownership of the medical practices. Based on the provisions of the management agreements, the medical practices are variable interest entities for which the Company is the primary beneficiary.

XML

Redeemable Non-Controlling Interests (Tables)

3 Months Ended

Mar. 31, 2024

Noncontrolling Interest [Abstract]

Schedule of redeemable non-controlling interests

The changes in redeemable non-controlling interests are as follows:

	Three Months Ended March 31,
	2023		2024
	(in thousands)
Balance as of January 1	$	34,043	$	26,297
Net income attributable to redeemable non-controlling interests	1,641		2,425
Distributions to redeemable non-controlling interests	(1,900)		(2,333)
Redemption value adjustment on redeemable non-controlling interests	436		1,901
Other	179		—
Balance as of March 31	$	34,399	$	28,290

XML

Leases (Tables)

3 Months Ended

Mar. 31, 2024

Leases [Abstract]

Schedule of lease cost

The Company’s total lease cost is as follows:

	Three Months Ended March 31, 2023						Three Months Ended March 31, 2024
	Unrelated Parties		Related Parties		Total		Unrelated Parties		Related Parties		Total
	(in thousands)
Operating lease cost	$	76,632	$	1,834	$	78,466	$	79,055	$	1,834	$	80,889
Finance lease cost:
Amortization of right-of-use assets	394		—		394		354		—		354
Interest on lease liabilities	320		—		320		304		—		304
Variable lease cost	15,761		84		15,845		17,076		—		17,076
Sublease income	(1,678)		—		(1,678)		(1,760)		—		(1,760)
Total lease cost	$	91,429	$	1,918	$	93,347	$	95,029	$	1,834	$	96,863

XML

Long-Term Debt and Notes Payable (Tables)

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Schedule of long-term debt and notes payable

As of March 31, 2024, the Company’s long-term debt and notes payable are as follows:

	Principal Outstanding		Unamortized Premium (Discount)		Unamortized Issuance Costs		Carrying Value		Fair Value
	(in thousands)
6.250% senior notes	$	1,225,000	$	14,041	$	(7,186)	$	1,231,855	$	1,226,531
Credit facilities:
Revolving facility	510,000		—		—		510,000		506,175
Term loan	2,013,400		(11,088)		(2,973)		1,999,339		2,015,917
Other debt, including finance leases	77,667		—		(46)		77,621		77,621
Total debt	$	3,826,067	$	2,953	$	(10,205)	$	3,818,815	$	3,826,244

As of December 31, 2023, the Company’s long-term debt and notes payable are as follows:

	Principal Outstanding		Unamortized Premium (Discount)		Unamortized Issuance Costs		Carrying Value		Fair Value
	(in thousands)
6.250% senior notes	$	1,225,000	$	15,533	$	(7,937)	$	1,232,596	$	1,228,063
Credit facilities:
Revolving facility	280,000		—		—		280,000		278,600
Term loan	2,092,485		(12,040)		(3,229)		2,077,216		2,092,485
Other debt, including finance leases	68,255		—		(63)		68,192		68,192
Total debt	$	3,665,740	$	3,493	$	(11,229)	$	3,658,004	$	3,667,340

Schedule of principal maturities of long-term debt and notes payable

Principal maturities of the Company’s long-term debt and notes payable are approximately as follows:

	2024		2025		2026		2027		2028		Thereafter		Total
	(in thousands)
6.250% senior notes	$	—	$	—	$	1,225,000	$	—	$	—	$	—	$	1,225,000
Credit facilities:
Revolving facility	—		—		—		510,000		—		—		510,000
Term loan	—		—		—		2,013,400		—		—		2,013,400
Other debt, including finance leases	58,155		3,151		2,461		1,941		1,620		10,339		77,667
Total debt	$	58,155	$	3,151	$	1,227,461	$	2,525,341	$	1,620	$	10,339	$	3,826,067

XML

Accrued and other liabilities (Tables)

3 Months Ended

Mar. 31, 2024

Payables and Accruals [Abstract]

Components of accrued and other liabilities

The following table sets forth the components of accrued and other liabilities on the Condensed Consolidated Balance Sheets:

	December 31, 2023		March 31, 2024
Accrued payroll	$	238,768	$	184,801
Accrued vacation	157,748		164,113
Accrued interest	32,472		14,438
Accrued other	297,663		292,587
Income taxes payable	1,499		30,552
Accrued and other liabilities	$	728,150	$	686,491

XML

Interest Rate Cap (Tables)

3 Months Ended

Mar. 31, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of accumulated other comprehensive income (loss)

The following table outlines the changes in accumulated other comprehensive income (loss), net of tax, during the periods presented:

	Three Months Ended March 31,
	2023		2024
	(in thousands)
Balance as of January 1	$	88,602	$	42,907
Gain (loss) on interest rate cap cash flow hedge	(2,696)		4,370
Amounts reclassified from accumulated other comprehensive income	(13,252)		(16,347)
Balance as of March 31	$	72,654	$	30,930

Schedule of reclassification out of accumulated other comprehensive income

The effects on net income of amounts reclassified from accumulated other comprehensive income are as follows:

		Three Months Ended March 31,
Statement of Operations		2023		2024
	(in thousands)
Gains included in interest expense		$	17,552	$	21,509
Income tax expense		(4,300)		(5,162)
Amounts reclassified from accumulated other comprehensive income		$	13,252	$	16,347

XML

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Schedule of interest rate cap

Financial Instrument	Balance Sheet Classification	Level	December 31, 2023		March 31, 2024
Asset:			(in thousands)
Interest rate cap contract, current portion	Current portion of interest rate cap contract	Level 2	$	58,962	$	42,660

Schedule of long-term debt

		December 31, 2023				March 31, 2024
Financial Instrument	Level	Carrying Value		Fair Value		Carrying Value		Fair Value
		(in thousands)
6.250% senior notes	Level 2	$	1,232,596	$	1,228,063	$	1,231,855	$	1,226,531
Credit facilities:
Revolving facility	Level 2	280,000		278,600		510,000		506,175
Term loan	Level 2	2,077,216		2,092,485		1,999,339		2,015,917

XML

Segment Information (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Schedule of selected financial data for reportable segments

The following tables summarize selected financial data for the Company’s reportable segments.

	Three Months Ended March 31,
	2023		2024
	(in thousands)
Revenue:
Critical illness recovery hospital	$	593,926	$	655,880
Rehabilitation hospital	231,462		265,700
Outpatient rehabilitation	295,903		303,158
Concentra	456,298		467,598
Other	87,391		96,473
Total Company	$	1,664,980	$	1,788,809
Adjusted EBITDA:
Critical illness recovery hospital	$	76,773	$	115,940
Rehabilitation hospital	47,216		61,400
Outpatient rehabilitation	30,199		24,928
Concentra	93,748		96,142
Other	(33,873)		(36,493)
Total Company	$	214,063	$	261,917
Total assets:
Critical illness recovery hospital	$	2,507,265	$	2,608,979
Rehabilitation hospital	1,203,069		1,233,828
Outpatient rehabilitation	1,397,823		1,423,740
Concentra	2,300,632		2,362,848
Other	290,947		228,868
Total Company	$	7,699,736	$	7,858,263
Purchases of property, equipment, and other assets:
Critical illness recovery hospital	$	23,658	$	15,941
Rehabilitation hospital	8,582		7,101
Outpatient rehabilitation	9,932		9,500
Concentra	14,400		17,231
Other	2,313		2,744
Total Company	$	58,885	$	52,517

Schedule of reconciliation of Adjusted EBITDA to income before income taxes

A reconciliation of Adjusted EBITDA to income before income taxes is as follows:

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Adjusted EBITDA	$	76,773	$	47,216	$	30,199	$	93,748	$	(33,873)
Depreciation and amortization	(16,637)		(6,888)		(8,457)		(18,310)		(2,133)
Stock compensation expense	—		—		—		(178)		(10,003)
Income (loss) from operations	$	60,136	$	40,328	$	21,742	$	75,260	$	(46,009)	$	151,457
Equity in earnings of unconsolidated subsidiaries											8,556
Interest expense											(48,571)
Income before income taxes											$	111,442

	Three Months Ended March 31, 2024
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Adjusted EBITDA	$	115,940	$	61,400	$	24,928	$	96,142	$	(36,493)
Depreciation and amortization	(17,157)		(7,135)		(9,181)		(18,485)		(2,111)
Stock compensation expense	—		—		—		(166)		(11,444)
Concentra separation transaction costs(1)	—		—		—		(1,993)		(278)
Income (loss) from operations	$	98,783	$	54,265	$	15,747	$	75,498	$	(50,326)	$	193,967
Equity in earnings of unconsolidated subsidiaries											10,421
Interest expense											(50,763)
Income before income taxes											$	153,625

_______________________________________________________________________________

(1)    Concentra separation transaction costs represent incremental consulting, legal, and audit-related fees incurred in connection with the Company’s planned separation of the Concentra segment into a new, publicly traded company and are included within general and administrative expenses on the Condensed Consolidated Statements of Operations.

XML

Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following tables disaggregate the Company’s revenue for the three months ended March 31, 2023 and 2024:

	Three Months Ended March 31, 2023
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Patient service revenue:
Medicare	$	229,383	$	110,055	$	45,801	$	243	$	—	$	385,482
Non-Medicare	363,305		109,925		231,985		454,598		—		1,159,813
Total patient services revenues	592,688		219,980		277,786		454,841		—		1,545,295
Other revenue	1,238		11,482		18,117		1,457		87,391		119,685
Total revenue	$	593,926	$	231,462	$	295,903	$	456,298	$	87,391	$	1,664,980

	Three Months Ended March 31, 2024
	Critical Illness Recovery Hospital		Rehabilitation Hospital		Outpatient Rehabilitation		Concentra		Other		Total
	(in thousands)
Patient service revenue:
Medicare	$	226,261	$	126,386	$	45,841	$	266	$	—	$	398,754
Non-Medicare	428,666		126,577		239,613		465,601		—		1,260,457
Total patient services revenues	654,927		252,963		285,454		465,867		—		1,659,211
Other revenue	953		12,737		17,704		1,731		96,473		129,598
Total revenue	$	655,880	$	265,700	$	303,158	$	467,598	$	96,473	$	1,788,809

XML

Earnings per Share (Tables)

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Schedule of computation of basic and diluted earnings per share

The following table sets forth the net income attributable to the Company, its common shares outstanding, and its participating securities outstanding.

	Basic and Diluted EPS
		Three Months Ended March 31,
		2023		2024
	(in thousands)
Net income		$	85,257	$	117,167
Less: net income attributable to non-controlling interests		14,452		20,270
Net income attributable to the Company		70,805		96,897
Less: Distributed and undistributed income attributable to participating securities		2,573		3,398
Distributed and undistributed income attributable to common shares		$	68,232	$	93,499

The following tables set forth the computation of EPS under the two-class method:

	Three Months Ended March 31,
	2023					2024
	Net Income Allocation		Shares(1)	Basic and Diluted EPS		Net Income Allocation		Shares(1)	Basic and Diluted EPS
	(in thousands, except for per share amounts)
Common shares	$	68,232	122,553	$	0.56	$	93,499	123,859	$	0.75
Participating securities	2,573		4,622	$	0.56	3,398		4,501	$	0.75
Total Company	$	70,805				$	96,897

_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

(1)    Represents the weighted average share count outstanding during the period.

XML

Credit Risk Concentrations (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Medicare Receivable | Credit Concentration Risk | Accounts Receivable
Concentration Risk [Line Items]
Percentage of concentration risk	20.00%	17.00%

XML

Redeemable Non-Controlling Interests (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Increase (Decrease) in Temporary Equity [Roll Forward]
Balance, beginning	$ 26,297	$ 34,043
Net income attributable to redeemable non-controlling interests	2,425	1,641
Distributions to redeemable non-controlling interests	(2,333)	(1,900)
Redemption value adjustment on redeemable non-controlling interests	1,901	436
Other	0	179
Balance, ending	$ 28,290	$ 34,399

XML

Variable Interest Entities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023
Variable Interest Entity [Line Items]
Assets	$ 7,858,263	$ 7,689,631	$ 7,699,736
Liabilities	6,192,330	6,115,616
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Assets	263,700	246,400
Liabilities	85,400	84,300
Variable Interest Entity, Primary Beneficiary | Related Party
Variable Interest Entity [Line Items]
Obligations payable	$ 179,500	$ 161,800

XML

Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating lease cost
Unrelated Parties	$ 79,055	$ 76,632
Related Parties	1,834	1,834
Total	80,889	78,466
Amortization of right-of-use assets
Unrelated Parties	354	394
Related Parties	0	0
Total	354	394
Interest on lease liabilities
Unrelated Parties	304	320
Related Parties	0	0
Total	304	320
Variable lease cost
Unrelated Parties	17,076	15,761
Related Parties	0	84
Total	17,076	15,845
Sublease income
Unrelated Parties	(1,760)	(1,678)
Related Parties	0	0
Total	(1,760)	(1,678)
Total lease cost
Unrelated Parties	95,029	91,429
Related Parties	1,834	1,918
Total	$ 96,863	$ 93,347

XML

Long-Term Debt and Notes Payable - Components of Long-Term Debt And Notes Payable (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Principal Outstanding	$ 3,826,067	$ 3,665,740
Unamortized Premium (Discount)	2,953	3,493
Unamortized Issuance Costs	(10,205)	(11,229)
Carrying Value	3,818,815	3,658,004
Fair Value	$ 3,826,244	$ 3,667,340
Senior notes | 6.250% senior notes
Debt Instrument [Line Items]
Interest rate of debt (as a percent)	6.25%	6.25%
Principal Outstanding	$ 1,225,000	$ 1,225,000
Unamortized Premium (Discount)	14,041	15,533
Unamortized Issuance Costs	(7,186)	(7,937)
Carrying Value	1,231,855	1,232,596
Fair Value	1,226,531	1,228,063
Term loan
Debt Instrument [Line Items]
Principal Outstanding	2,013,400	2,092,485
Unamortized Premium (Discount)	(11,088)	(12,040)
Unamortized Issuance Costs	(2,973)	(3,229)
Carrying Value	1,999,339	2,077,216
Fair Value	2,015,917	2,092,485
Other debt, including finance leases
Debt Instrument [Line Items]
Principal Outstanding	77,667	68,255
Unamortized Premium (Discount)	0	0
Unamortized Issuance Costs	(46)	(63)
Carrying Value	77,621	68,192
Fair Value	77,621	68,192
Revolving facility | Revolving facility
Debt Instrument [Line Items]
Principal Outstanding	510,000	280,000
Unamortized Premium (Discount)	0	0
Unamortized Issuance Costs	0	0
Carrying Value	510,000	280,000
Fair Value	$ 506,175	$ 278,600

XML

Long-Term Debt and Notes Payable - Principal Maturities Of Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
2024	$ 58,155
2025	3,151
2026	1,227,461
2027	2,525,341
2028	1,620
Thereafter	10,339
Total	$ 3,826,067	$ 3,665,740
Senior notes | 6.250% senior notes
Debt Instrument [Line Items]
Interest rate of debt (as a percent)	6.25%	6.25%
2024	$ 0
2025	0
2026	1,225,000
2027	0
2028	0
Thereafter	0
Total	1,225,000	$ 1,225,000
Revolving facility | Revolving facility
Debt Instrument [Line Items]
2024	0
2025	0
2026	0
2027	510,000
2028	0
Thereafter	0
Total	510,000	280,000
Term loan
Debt Instrument [Line Items]
2024	0
2025	0
2026	0
2027	2,013,400
2028	0
Thereafter	0
Total	2,013,400	2,092,485
Other debt, including finance leases
Debt Instrument [Line Items]
2024	58,155
2025	3,151
2026	2,461
2027	1,941
2028	1,620
Thereafter	10,339
Total	$ 77,667	$ 68,255

XML

Accrued and other liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued payroll	$ 184,801	$ 238,768
Accrued vacation	164,113	157,748
Accrued interest	14,438	32,472
Accrued other	292,587	297,663
Income taxes payable	30,552	1,499
Accrued and other liabilities	$ 686,491	$ 728,150

XML

Interest Rate Cap - Narrative (Details) - Interest Rate Cap $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Derivative [Line Items]
Derivative cap interest rate (as a percent)	1.00%
Notional amount	$ 2,000.0
Annual premium (in percent)	0.000916
Annual premium amount	$ 1.8
Estimated pre-tax gain expected to be reclassified through expiration	$ 40.7

XML

Interest Rate Cap - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 1,547,718	$ 1,356,564
Ending balance	1,637,643	1,418,441
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | Interest Rate Cap
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	42,907	88,602
Gain (loss) on interest rate cap cash flow hedge	4,370	(2,696)
Amounts reclassified from accumulated other comprehensive income	(16,347)	(13,252)
Ending balance	$ 30,930	$ 72,654

XML

Interest Rate Cap - Schedule of Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Gains included in interest expense	$ (50,763)	$ (48,571)
Income tax expense	(36,458)	(26,185)
Amounts reclassified from accumulated other comprehensive income	96,897	70,805
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | Interest Rate Cap
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Gains included in interest expense	21,509	17,552
Income tax expense	(5,162)	(4,300)
Amounts reclassified from accumulated other comprehensive income	$ 16,347	$ 13,252

XML

Fair Value of Financial Instruments - Schedule of Interest Rate Cap (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate cap contract, current portion	$ 42,660	$ 58,962
Interest Rate Cap | Fair Value, Inputs, Level 2 | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest rate cap contract, current portion	$ 42,660	$ 58,962

XML

Fair Value of Financial Instruments - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 3,826,244	$ 3,667,340
Senior notes | 6.250% senior notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate of debt (as a percent)	6.25%	6.25%
Carrying Value	$ 1,231,855	$ 1,232,596
Fair Value	1,226,531	1,228,063
Senior notes | Fair Value, Inputs, Level 2 | 6.250% senior notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	1,231,855	1,232,596
Fair Value	1,226,531	1,228,063
Revolving facility | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	510,000	280,000
Fair Value	506,175	278,600
Term loan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	1,999,339	2,077,216
Fair Value	2,015,917	2,092,485
Term loan | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	1,999,339	2,077,216
Fair Value	$ 2,015,917	$ 2,092,485

XML

Segment Information - Selected Financial Data (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Segment Reporting Information [Line Items]
Revenue	$ 1,788,809	$ 1,664,980
Adjusted EBITDA	261,917	214,063
Total assets	7,858,263	7,699,736	$ 7,689,631
Purchases of property, equipment, and other assets	52,517	58,885
Operating Segments | Critical Illness Recovery Hospital
Segment Reporting Information [Line Items]
Revenue	655,880	593,926
Adjusted EBITDA	115,940	76,773
Total assets	2,608,979	2,507,265
Purchases of property, equipment, and other assets	15,941	23,658
Operating Segments | Rehabilitation Hospital
Segment Reporting Information [Line Items]
Revenue	265,700	231,462
Adjusted EBITDA	61,400	47,216
Total assets	1,233,828	1,203,069
Purchases of property, equipment, and other assets	7,101	8,582
Operating Segments | Outpatient Rehabilitation
Segment Reporting Information [Line Items]
Revenue	303,158	295,903
Adjusted EBITDA	24,928	30,199
Total assets	1,423,740	1,397,823
Purchases of property, equipment, and other assets	9,500	9,932
Operating Segments | Concentra
Segment Reporting Information [Line Items]
Revenue	467,598	456,298
Adjusted EBITDA	96,142	93,748
Total assets	2,362,848	2,300,632
Purchases of property, equipment, and other assets	17,231	14,400
Other
Segment Reporting Information [Line Items]
Revenue	96,473	87,391
Adjusted EBITDA	(36,493)	(33,873)
Total assets	228,868	290,947
Purchases of property, equipment, and other assets	$ 2,744	$ 2,313

XML

Segment Information - Reconciliation of Adjusted EBITDA to Income Before Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Adjusted EBITDA	$ 261,917	$ 214,063
Depreciation and amortization	(54,069)	(52,425)
Income from operations	193,967	151,457
Equity in earnings of unconsolidated subsidiaries	10,421	8,556
Interest expense	(50,763)	(48,571)
Income before income taxes	153,625	111,442
Operating Segments | Critical Illness Recovery Hospital
Segment Reporting Information [Line Items]
Adjusted EBITDA	115,940	76,773
Depreciation and amortization	(17,157)	(16,637)
Stock compensation expense	0	0
Concentra separation transaction costs	0
Income from operations	98,783	60,136
Operating Segments | Rehabilitation Hospital
Segment Reporting Information [Line Items]
Adjusted EBITDA	61,400	47,216
Depreciation and amortization	(7,135)	(6,888)
Stock compensation expense	0	0
Concentra separation transaction costs	0
Income from operations	54,265	40,328
Operating Segments | Outpatient Rehabilitation
Segment Reporting Information [Line Items]
Adjusted EBITDA	24,928	30,199
Depreciation and amortization	(9,181)	(8,457)
Stock compensation expense	0	0
Concentra separation transaction costs	0
Income from operations	15,747	21,742
Operating Segments | Concentra
Segment Reporting Information [Line Items]
Adjusted EBITDA	96,142	93,748
Depreciation and amortization	(18,485)	(18,310)
Stock compensation expense	(166)	(178)
Concentra separation transaction costs	(1,993)
Income from operations	75,498	75,260
Other
Segment Reporting Information [Line Items]
Adjusted EBITDA	(36,493)	(33,873)
Depreciation and amortization	(2,111)	(2,133)
Stock compensation expense	(11,444)	(10,003)
Concentra separation transaction costs	(278)
Income from operations	$ (50,326)	$ (46,009)

XML

Revenue from Contracts with Customers (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,788,809	$ 1,664,980
Total patient services revenues
Disaggregation of Revenue [Line Items]
Total revenue	1,659,211	1,545,295
Medicare
Disaggregation of Revenue [Line Items]
Total revenue	398,754	385,482
Non-Medicare
Disaggregation of Revenue [Line Items]
Total revenue	1,260,457	1,159,813
Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	129,598	119,685
Operating Segments | Critical Illness Recovery Hospital
Disaggregation of Revenue [Line Items]
Total revenue	655,880	593,926
Operating Segments | Critical Illness Recovery Hospital | Total patient services revenues
Disaggregation of Revenue [Line Items]
Total revenue	654,927	592,688
Operating Segments | Critical Illness Recovery Hospital | Medicare
Disaggregation of Revenue [Line Items]
Total revenue	226,261	229,383
Operating Segments | Critical Illness Recovery Hospital | Non-Medicare
Disaggregation of Revenue [Line Items]
Total revenue	428,666	363,305
Operating Segments | Critical Illness Recovery Hospital | Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	953	1,238
Operating Segments | Rehabilitation Hospital
Disaggregation of Revenue [Line Items]
Total revenue	265,700	231,462
Operating Segments | Rehabilitation Hospital | Total patient services revenues
Disaggregation of Revenue [Line Items]
Total revenue	252,963	219,980
Operating Segments | Rehabilitation Hospital | Medicare
Disaggregation of Revenue [Line Items]
Total revenue	126,386	110,055
Operating Segments | Rehabilitation Hospital | Non-Medicare
Disaggregation of Revenue [Line Items]
Total revenue	126,577	109,925
Operating Segments | Rehabilitation Hospital | Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	12,737	11,482
Operating Segments | Outpatient Rehabilitation
Disaggregation of Revenue [Line Items]
Total revenue	303,158	295,903
Operating Segments | Outpatient Rehabilitation | Total patient services revenues
Disaggregation of Revenue [Line Items]
Total revenue	285,454	277,786
Operating Segments | Outpatient Rehabilitation | Medicare
Disaggregation of Revenue [Line Items]
Total revenue	45,841	45,801
Operating Segments | Outpatient Rehabilitation | Non-Medicare
Disaggregation of Revenue [Line Items]
Total revenue	239,613	231,985
Operating Segments | Outpatient Rehabilitation | Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	17,704	18,117
Operating Segments | Concentra
Disaggregation of Revenue [Line Items]
Total revenue	467,598	456,298
Operating Segments | Concentra | Total patient services revenues
Disaggregation of Revenue [Line Items]
Total revenue	465,867	454,841
Operating Segments | Concentra | Medicare
Disaggregation of Revenue [Line Items]
Total revenue	266	243
Operating Segments | Concentra | Non-Medicare
Disaggregation of Revenue [Line Items]
Total revenue	465,601	454,598
Operating Segments | Concentra | Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	1,731	1,457
Other
Disaggregation of Revenue [Line Items]
Total revenue	96,473	87,391
Other | Total patient services revenues
Disaggregation of Revenue [Line Items]
Total revenue	0	0
Other | Medicare
Disaggregation of Revenue [Line Items]
Total revenue	0	0
Other | Non-Medicare
Disaggregation of Revenue [Line Items]
Total revenue	0	0
Other | Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	$ 96,473	$ 87,391

XML

Earnings per Share - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Earnings Per Share [Abstract]
Contractual dividends paid	$ 0	$ 0

XML

Earnings per Share - Net Income Attributable to the Company, Common Shares Outstanding, and Participating Securities Outstanding (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Earnings Per Share [Abstract]
Net income	$ 117,167	$ 85,257
Less: Net income attributable to non-controlling interests	20,270	14,452
Net income attributable to Select Medical Holdings Corporation	96,897	70,805
Basic EPS
Less: Distributed and undistributed income attributable to participating securities - Basic EPS	3,398	2,573
Distributed and undistributed income attributable to common shares	93,499	68,232
Diluted EPS
Less: Distributed and undistributed income attributable to participating securities - Diluted EPS	3,398	2,573
Distributed and undistributed income attributable to common shares	$ 93,499	$ 68,232

XML

Earnings per Share - Computation of EPS Under the Two-Class Method (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net Income Allocation
Net income allocated to common shares - basic	$ 93,499	$ 68,232
Participating securities - basic	3,398	2,573
Net income allocated to common shares - diluted	93,499	68,232
Participating securities - diluted	3,398	2,573
Net income attributable to Select Medical Holdings Corporation	$ 96,897	$ 70,805
Weighted average common shares outstanding, basic (in shares)	123,859	122,553
Weighted average common shares outstanding, diluted (in shares)	123,859	122,553
Weighted average participating securities outstanding (in shares)	4,501	4,622
Basic EPS
Basic EPS (in dollars per share)	$ 0.75	$ 0.56
Diluted EPS
Diluted EPS (in dollars per share)	$ 0.75	$ 0.56

XML

Commitments and Contingencies (Details) $ in Millions	1 Months Ended	3 Months Ended
	Feb. 29, 2024 class_action_lawsuit patient	Mar. 31, 2024 USD ($)
Commitments and Contingencies
Number of patients | patient	4,000,000
Number of class action lawsuits | class_action_lawsuit	6
Professional liability claims | Critical Illness Recovery Hospitals, Rehabilitation Hospitals And Outpatient Rehabilitiation
Commitments and Contingencies
Total annual aggregate limit of insurance coverage		$ 37.0
Professional liability claims | Concentra
Commitments and Contingencies
Total annual aggregate limit of insurance coverage		29.0
Professional liability claims | Joint Venture Operations
Commitments and Contingencies
Total annual aggregate limit of insurance coverage		80.0
Professional liability claims | Joint Venture Operations | Minimum
Commitments and Contingencies
Total annual aggregate limit of insurance coverage		23.0
Professional liability claims | Joint Venture Operations | Maximum
Commitments and Contingencies
Total annual aggregate limit of insurance coverage		33.0
General Liability | Critical Illness Recovery Hospitals, Rehabilitation Hospitals And Outpatient Rehabilitiation
Commitments and Contingencies
Total annual aggregate limit of insurance coverage		40.0
General Liability | Concentra
Commitments and Contingencies
Total annual aggregate limit of insurance coverage		$ 29.0

XML

Subsequent Events (Details)	May 01, 2024 $ / shares
Subsequent Event
Subsequent Event [Line Items]
Cash dividend declared (in dollars per share)	$ 0.125